id	sid	tid	token	lemma	pos
hsn-1065	1	1	ijo	ijo	PROPN
hsn-1065	1	2	international	international	PROPN
hsn-1065	1	3	journal	journal	PROPN
hsn-1065	1	4	of	of	ADP
hsn-1065	1	5	health	health	PROPN
hsn-1065	1	6	sciences	sciences	PROPN
hsn-1065	1	7	and	and	CCONJ
hsn-1065	1	8	nursing	nursing	NOUN
hsn-1065	1	9	(	(	PUNCT
hsn-1065	1	10	issn	issn	PROPN
hsn-1065	1	11	:	:	PUNCT
hsn-1065	1	12	2814	2814	NUM
hsn-1065	1	13	-	-	SYM
hsn-1065	1	14	2098	2098	NUM
hsn-1065	1	15	)	)	PUNCT
hsn-1065	1	16	chinedu	chinedu	NOUN
hsn-1065	1	17	-	-	PUNCT
hsn-1065	1	18	madu	madu	NOUN
hsn-1065	1	19	jane	jane	NOUN
hsn-1065	1	20	u	u	NOUN
hsn-1065	1	21	1	1	NUM
hsn-1065	1	22	*	*	PUNCT
hsn-1065	1	23	https://ijojournals.com/	https://ijojournals.com/	NOUN
hsn-1065	1	24	volume	volume	NOUN
hsn-1065	1	25	08	08	NUM
hsn-1065	1	26	||	||	PROPN
hsn-1065	1	27	issue	issue	NOUN
hsn-1065	1	28	04	04	NUM
hsn-1065	1	29	||	||	NOUN
hsn-1065	1	30	april	april	PROPN
hsn-1065	1	31	,	,	PUNCT
hsn-1065	1	32	2025	2025	NUM
hsn-1065	1	33	||	||	PUNCT
hsn-1065	2	1	“	"	PUNCT
hsn-1065	2	2	studies	study	NOUN
hsn-1065	2	3	on	on	ADP
hsn-1065	2	4	activated	activate	VERB
hsn-1065	2	5	partial	partial	ADJ
hsn-1065	2	6	thromboplastin	thromboplastin	NOUN
hsn-1065	2	7	time	time	NOUN
hsn-1065	2	8	,	,	PUNCT
hsn-1065	2	9	red	red	ADJ
hsn-1065	2	10	and	and	CCONJ
hsn-1065	2	11	white	white	ADJ
hsn-1065	2	12	blood	blood	NOUN
hsn-1065	2	13	cell	cell	NOUN
hsn-1065	2	14	counts	count	NOUN
hsn-1065	2	15	in	in	ADP
hsn-1065	2	16	coronary	coronary	ADJ
hsn-1065	2	17	artery	artery	NOUN
hsn-1065	2	18	disease	disease	NOUN
hsn-1065	2	19	in	in	ADP
hsn-1065	2	20	owerri	owerri	PROPN
hsn-1065	2	21	,	,	PUNCT
hsn-1065	2	22	nigeria	nigeria	PROPN
hsn-1065	2	23	..	..	PUNCT
hsn-1065	2	24	"	"	PUNCT
hsn-1065	3	1	studies	study	NOUN
hsn-1065	3	2	on	on	ADP
hsn-1065	3	3	activated	activate	VERB
hsn-1065	3	4	partial	partial	ADJ
hsn-1065	3	5	thromboplastin	thromboplastin	NOUN
hsn-1065	3	6	time	time	NOUN
hsn-1065	3	7	,	,	PUNCT
hsn-1065	3	8	red	red	ADJ
hsn-1065	3	9	and	and	CCONJ
hsn-1065	3	10	white	white	ADJ
hsn-1065	3	11	blood	blood	NOUN
hsn-1065	3	12	cell	cell	NOUN
hsn-1065	3	13	counts	count	NOUN
hsn-1065	3	14	in	in	ADP
hsn-1065	3	15	coronary	coronary	ADJ
hsn-1065	3	16	artery	artery	NOUN
hsn-1065	3	17	disease	disease	NOUN
hsn-1065	3	18	in	in	ADP
hsn-1065	3	19	owerri	owerri	PROPN
hsn-1065	3	20	,	,	PUNCT
hsn-1065	3	21	nigeria	nigeria	PROPN
hsn-1065	3	22	.	.	PUNCT
hsn-1065	4	1	chinedu	chinedu	NOUN
hsn-1065	4	2	-	-	PUNCT
hsn-1065	4	3	madu	madu	NOUN
hsn-1065	4	4	jane	jane	NOUN
hsn-1065	4	5	u1	u1	NOUN
hsn-1065	4	6	,	,	PUNCT
hsn-1065	4	7	onyejiawa	onyejiawa	PRON
hsn-1065	4	8	favour	favour	VERB
hsn-1065	4	9	c.2	c.2	PROPN
hsn-1065	4	10	,	,	PUNCT
hsn-1065	4	11	and	and	CCONJ
hsn-1065	4	12	aloy	aloy	NOUN
hsn-1065	4	13	-	-	PUNCT
hsn-1065	4	14	amadi	amadi	NOUN
hsn-1065	4	15	oluchi	oluchi	PROPN
hsn-1065	4	16	c3	c3	PROPN
hsn-1065	4	17	.	.	PUNCT
hsn-1065	5	1	1department	1department	NUM
hsn-1065	5	2	of	of	ADP
hsn-1065	5	3	haematology	haematology	NOUN
hsn-1065	5	4	,	,	PUNCT
hsn-1065	5	5	federal	federal	ADJ
hsn-1065	5	6	university	university	NOUN
hsn-1065	5	7	otueke	otueke	NOUN
hsn-1065	5	8	,	,	PUNCT
hsn-1065	5	9	bayelsa	bayelsa	NOUN
hsn-1065	5	10	state	state	NOUN
hsn-1065	5	11	,	,	PUNCT
hsn-1065	5	12	nigeria	nigeria	PROPN
hsn-1065	5	13	.	.	PUNCT
hsn-1065	6	1	2	2	NUM
hsn-1065	6	2	,	,	PUNCT
hsn-1065	6	3	3	3	NUM
hsn-1065	6	4	department	department	NOUN
hsn-1065	6	5	of	of	ADP
hsn-1065	6	6	medical	medical	ADJ
hsn-1065	6	7	laboratory	laboratory	NOUN
hsn-1065	6	8	science	science	NOUN
hsn-1065	6	9	,	,	PUNCT
hsn-1065	6	10	imo	imo	PROPN
hsn-1065	6	11	state	state	PROPN
hsn-1065	6	12	university	university	PROPN
hsn-1065	6	13	,	,	PUNCT
hsn-1065	6	14	owerri	owerri	PROPN
hsn-1065	6	15	,	,	PUNCT
hsn-1065	6	16	nigeria	nigeria	PROPN
hsn-1065	6	17	.	.	PUNCT
hsn-1065	7	1	corresponding	correspond	VERB
hsn-1065	7	2	author	author	NOUN
hsn-1065	7	3	:	:	PUNCT
hsn-1065	7	4	chinedu	chinedu	NOUN
hsn-1065	7	5	-	-	PUNCT
hsn-1065	7	6	madu	madu	NOUN
hsn-1065	7	7	jane	jane	NOUN
hsn-1065	7	8	u.	u.	PROPN
hsn-1065	7	9	abstract	abstract	PROPN
hsn-1065	7	10	background	background	NOUN
hsn-1065	7	11	:	:	PUNCT
hsn-1065	7	12	coronary	coronary	ADJ
hsn-1065	7	13	artery	artery	NOUN
hsn-1065	7	14	disease	disease	NOUN
hsn-1065	7	15	(	(	PUNCT
hsn-1065	7	16	cad	cad	NOUN
hsn-1065	7	17	)	)	PUNCT
hsn-1065	7	18	is	be	AUX
hsn-1065	7	19	a	a	DET
hsn-1065	7	20	multifactorial	multifactorial	ADJ
hsn-1065	7	21	condition	condition	NOUN
hsn-1065	7	22	influenced	influence	VERB
hsn-1065	7	23	by	by	ADP
hsn-1065	7	24	cardiovascular	cardiovascular	ADJ
hsn-1065	7	25	,	,	PUNCT
hsn-1065	7	26	hematological	hematological	ADJ
hsn-1065	7	27	and	and	CCONJ
hsn-1065	7	28	haemostatic	haemostatic	ADJ
hsn-1065	7	29	factors	factor	NOUN
hsn-1065	7	30	.	.	PUNCT
hsn-1065	8	1	the	the	DET
hsn-1065	8	2	knowledge	knowledge	NOUN
hsn-1065	8	3	of	of	ADP
hsn-1065	8	4	these	these	DET
hsn-1065	8	5	parameters	parameter	NOUN
hsn-1065	8	6	in	in	ADP
hsn-1065	8	7	cad	cad	PROPN
hsn-1065	8	8	patients	patient	NOUN
hsn-1065	8	9	,	,	PUNCT
hsn-1065	8	10	including	include	VERB
hsn-1065	8	11	gender	gender	NOUN
hsn-1065	8	12	-	-	PUNCT
hsn-1065	8	13	based	base	VERB
hsn-1065	8	14	differences	difference	NOUN
hsn-1065	8	15	,	,	PUNCT
hsn-1065	8	16	is	be	AUX
hsn-1065	8	17	essential	essential	ADJ
hsn-1065	8	18	for	for	ADP
hsn-1065	8	19	personalized	personalized	ADJ
hsn-1065	8	20	diagnosis	diagnosis	NOUN
hsn-1065	8	21	and	and	CCONJ
hsn-1065	8	22	treatment	treatment	NOUN
hsn-1065	8	23	.	.	PUNCT
hsn-1065	9	1	objective	objective	NOUN
hsn-1065	9	2	:	:	PUNCT
hsn-1065	9	3	to	to	PART
hsn-1065	9	4	investigate	investigate	VERB
hsn-1065	9	5	red	red	ADJ
hsn-1065	9	6	cell	cell	NOUN
hsn-1065	9	7	indices	index	NOUN
hsn-1065	9	8	and	and	CCONJ
hsn-1065	9	9	aspartate	aspartate	NOUN
hsn-1065	9	10	aminotransferase	aminotransferase	PROPN
hsn-1065	9	11	in	in	ADP
hsn-1065	9	12	cad	cad	PROPN
hsn-1065	9	13	patients	patient	NOUN
hsn-1065	9	14	federal	federal	ADJ
hsn-1065	9	15	teaching	teaching	NOUN
hsn-1065	9	16	hospital	hospital	NOUN
hsn-1065	9	17	,	,	PUNCT
hsn-1065	9	18	owerri	owerri	PROPN
hsn-1065	9	19	,	,	PUNCT
hsn-1065	9	20	nigeria	nigeria	PROPN
hsn-1065	9	21	,	,	PUNCT
hsn-1065	9	22	and	and	CCONJ
hsn-1065	9	23	assess	assess	VERB
hsn-1065	9	24	gender	gender	NOUN
hsn-1065	9	25	-	-	PUNCT
hsn-1065	9	26	based	base	VERB
hsn-1065	9	27	variations	variation	NOUN
hsn-1065	9	28	.	.	PUNCT
hsn-1065	10	1	methods	method	NOUN
hsn-1065	10	2	:	:	PUNCT
hsn-1065	10	3	a	a	DET
hsn-1065	10	4	cross	cross	ADJ
hsn-1065	10	5	-	-	ADJ
hsn-1065	10	6	sectional	sectional	ADJ
hsn-1065	10	7	study	study	NOUN
hsn-1065	10	8	was	be	AUX
hsn-1065	10	9	conducted	conduct	VERB
hsn-1065	10	10	involving	involve	VERB
hsn-1065	10	11	30	30	NUM
hsn-1065	10	12	cad	cad	NOUN
hsn-1065	10	13	patients	patient	NOUN
hsn-1065	10	14	(	(	PUNCT
hsn-1065	10	15	19	19	NUM
hsn-1065	10	16	males	male	NOUN
hsn-1065	10	17	and	and	CCONJ
hsn-1065	10	18	11	11	NUM
hsn-1065	10	19	females	female	NOUN
hsn-1065	10	20	)	)	PUNCT
hsn-1065	10	21	and	and	CCONJ
hsn-1065	10	22	30	30	NUM
hsn-1065	10	23	age	age	NOUN
hsn-1065	10	24	-	-	PUNCT
hsn-1065	10	25	matched	match	VERB
hsn-1065	10	26	healthy	healthy	ADJ
hsn-1065	10	27	controls	control	NOUN
hsn-1065	10	28	.	.	PUNCT
hsn-1065	11	1	a	a	DET
hsn-1065	11	2	total	total	NOUN
hsn-1065	11	3	of	of	ADP
hsn-1065	11	4	5	5	NUM
hsn-1065	11	5	ml	ml	NOUN
hsn-1065	11	6	of	of	ADP
hsn-1065	11	7	venous	venous	ADJ
hsn-1065	11	8	blood	blood	NOUN
hsn-1065	11	9	was	be	AUX
hsn-1065	11	10	collected	collect	VERB
hsn-1065	11	11	from	from	ADP
hsn-1065	11	12	each	each	DET
hsn-1065	11	13	participant	participant	NOUN
hsn-1065	11	14	,	,	PUNCT
hsn-1065	11	15	with	with	ADP
hsn-1065	11	16	3	3	NUM
hsn-1065	11	17	ml	ml	NOUN
hsn-1065	11	18	placed	place	VERB
hsn-1065	11	19	in	in	ADP
hsn-1065	11	20	edta	edta	NOUN
hsn-1065	11	21	tubes	tube	NOUN
hsn-1065	11	22	for	for	ADP
hsn-1065	11	23	hematological	hematological	ADJ
hsn-1065	11	24	analysis	analysis	NOUN
hsn-1065	11	25	and	and	CCONJ
hsn-1065	11	26	2	2	NUM
hsn-1065	11	27	mls	mls	NOUN
hsn-1065	11	28	into	into	ADP
hsn-1065	11	29	sodium	sodium	NOUN
hsn-1065	11	30	citrate	citrate	NOUN
hsn-1065	11	31	containers	container	NOUN
hsn-1065	11	32	for	for	ADP
hsn-1065	11	33	aptt	aptt	ADJ
hsn-1065	11	34	determination	determination	NOUN
hsn-1065	11	35	..	..	PUNCT
hsn-1065	11	36	haematological	haematological	ADJ
hsn-1065	11	37	parameters	parameter	NOUN
hsn-1065	11	38	were	be	AUX
hsn-1065	11	39	assessed	assess	VERB
hsn-1065	11	40	using	use	VERB
hsn-1065	11	41	an	an	DET
hsn-1065	11	42	automated	automate	VERB
hsn-1065	11	43	hematology	hematology	NOUN
hsn-1065	11	44	analyzer	analyzer	NOUN
hsn-1065	11	45	,	,	PUNCT
hsn-1065	11	46	while	while	SCONJ
hsn-1065	11	47	aptt	aptt	PROPN
hsn-1065	11	48	was	be	AUX
hsn-1065	11	49	determined	determine	VERB
hsn-1065	11	50	using	use	VERB
hsn-1065	11	51	a	a	DET
hsn-1065	11	52	standard	standard	ADJ
hsn-1065	11	53	coagulometer	coagulometer	NOUN
hsn-1065	11	54	and	and	CCONJ
hsn-1065	11	55	commercial	commercial	ADJ
hsn-1065	11	56	reagents	reagent	NOUN
hsn-1065	11	57	according	accord	VERB
hsn-1065	11	58	to	to	ADP
hsn-1065	11	59	the	the	DET
hsn-1065	11	60	manufacturer	manufacturer	NOUN
hsn-1065	11	61	’s	’s	PART
hsn-1065	11	62	instructions	instruction	NOUN
hsn-1065	11	63	.	.	PUNCT
hsn-1065	11	64	.	.	PUNCT
hsn-1065	12	1	statistical	statistical	ADJ
hsn-1065	12	2	analysis	analysis	NOUN
hsn-1065	12	3	was	be	AUX
hsn-1065	12	4	conducted	conduct	VERB
hsn-1065	12	5	using	use	VERB
hsn-1065	12	6	independent	independent	ADJ
hsn-1065	12	7	t	t	NOUN
hsn-1065	12	8	-	-	PUNCT
hsn-1065	12	9	tests	test	NOUN
hsn-1065	12	10	to	to	PART
hsn-1065	12	11	compare	compare	VERB
hsn-1065	12	12	group	group	NOUN
hsn-1065	12	13	differences	difference	NOUN
hsn-1065	12	14	and	and	CCONJ
hsn-1065	12	15	pearson	pearson	NOUN
hsn-1065	12	16	correlation	correlation	NOUN
hsn-1065	12	17	for	for	ADP
hsn-1065	12	18	association	association	NOUN
hsn-1065	12	19	studies	study	NOUN
hsn-1065	12	20	,	,	PUNCT
hsn-1065	12	21	with	with	ADP
hsn-1065	12	22	p	p	X
hsn-1065	12	23	<	<	X
hsn-1065	12	24	0.05	0.05	NUM
hsn-1065	12	25	considered	consider	VERB
hsn-1065	12	26	statistically	statistically	ADV
hsn-1065	12	27	significant	significant	ADJ
hsn-1065	12	28	.	.	PUNCT
hsn-1065	13	1	results	result	NOUN
hsn-1065	13	2	:	:	PUNCT
hsn-1065	13	3	cad	cad	PROPN
hsn-1065	13	4	patients	patient	NOUN
hsn-1065	13	5	showed	show	VERB
hsn-1065	13	6	significantly	significantly	ADV
hsn-1065	13	7	higher	high	ADJ
hsn-1065	13	8	mean	mean	VERB
hsn-1065	13	9	activated	activate	VERB
hsn-1065	13	10	partial	partial	ADJ
hsn-1065	13	11	thromboplastin	thromboplastin	NOUN
hsn-1065	13	12	time	time	NOUN
hsn-1065	13	13	(	(	PUNCT
hsn-1065	13	14	aptt	aptt	ADV
hsn-1065	13	15	:	:	PUNCT
hsn-1065	13	16	41.23	41.23	NUM
hsn-1065	13	17	±	±	NUM
hsn-1065	13	18	4.09	4.09	NUM
hsn-1065	13	19	)	)	PUNCT
hsn-1065	13	20	secsand	secsand	ADJ
hsn-1065	13	21	white	white	ADJ
hsn-1065	13	22	blood	blood	NOUN
hsn-1065	13	23	cell	cell	NOUN
hsn-1065	13	24	(	(	PUNCT
hsn-1065	13	25	wbc	wbc	PROPN
hsn-1065	13	26	)	)	PUNCT
hsn-1065	13	27	count	count	NOUN
hsn-1065	13	28	(	(	PUNCT
hsn-1065	13	29	15.23	15.23	NUM
hsn-1065	13	30	±	±	NUM
hsn-1065	13	31	2.1	2.1	NUM
hsn-1065	13	32	)	)	PUNCT
hsn-1065	13	33	×	×	NOUN
hsn-1065	13	34	10	10	NUM
hsn-1065	13	35	/l	/l	PUNCT
hsn-1065	13	36	compared	compare	VERB
hsn-1065	13	37	to	to	ADP
hsn-1065	13	38	controls	control	NOUN
hsn-1065	13	39	(	(	PUNCT
hsn-1065	13	40	aptt	aptt	ADJ
hsn-1065	13	41	:	:	PUNCT
hsn-1065	13	42	28.30	28.30	NUM
hsn-1065	13	43	±	±	NUM
hsn-1065	13	44	2.17)secs	2.17)secs	NUM
hsn-1065	13	45	;	;	PUNCT
hsn-1065	13	46	wbc	wbc	PROPN
hsn-1065	13	47	:	:	PUNCT
hsn-1065	13	48	(	(	PUNCT
hsn-1065	13	49	7.00	7.00	NUM
hsn-1065	13	50	±	±	NUM
hsn-1065	13	51	1.68	1.68	NUM
hsn-1065	13	52	)	)	PUNCT
hsn-1065	13	53	×	×	NOUN
hsn-1065	13	54	10	10	NUM
hsn-1065	13	55	/l	/l	PUNCT
hsn-1065	13	56	with	with	ADP
hsn-1065	13	57	p	p	NOUN
hsn-1065	13	58	-	-	PUNCT
hsn-1065	13	59	values	value	NOUN
hsn-1065	13	60	of	of	ADP
hsn-1065	13	61	0.002	0.002	NUM
hsn-1065	13	62	and	and	CCONJ
hsn-1065	13	63	<	<	X
hsn-1065	13	64	0.001	0.001	NUM
hsn-1065	13	65	,	,	PUNCT
hsn-1065	13	66	respectively	respectively	ADV
hsn-1065	13	67	.	.	PUNCT
hsn-1065	14	1	red	red	ADJ
hsn-1065	14	2	blood	blood	NOUN
hsn-1065	14	3	cell	cell	NOUN
hsn-1065	14	4	(	(	PUNCT
hsn-1065	14	5	rbc	rbc	PROPN
hsn-1065	14	6	)	)	PUNCT
hsn-1065	14	7	count	count	NOUN
hsn-1065	14	8	was	be	AUX
hsn-1065	14	9	significantly	significantly	ADV
hsn-1065	14	10	lower	low	ADJ
hsn-1065	14	11	in	in	ADP
hsn-1065	14	12	cad	cad	PROPN
hsn-1065	14	13	patients	patient	NOUN
hsn-1065	14	14	(	(	PUNCT
hsn-1065	14	15	2.07	2.07	NUM
hsn-1065	14	16	±	±	NUM
hsn-1065	14	17	0.35	0.35	NUM
hsn-1065	14	18	)	)	PUNCT
hsn-1065	14	19	×	×	PROPN
hsn-1065	14	20	10¹²/l	10¹²/l	NOUN
hsn-1065	14	21	)	)	PUNCT
hsn-1065	14	22	compared	compare	VERB
hsn-1065	14	23	to	to	ADP
hsn-1065	14	24	controls	control	NOUN
hsn-1065	14	25	(	(	PUNCT
hsn-1065	14	26	4.01	4.01	NUM
hsn-1065	14	27	±	±	NUM
hsn-1065	14	28	0.27	0.27	NUM
hsn-1065	14	29	)	)	PUNCT
hsn-1065	14	30	×	×	PROPN
hsn-1065	14	31	10¹²/l	10¹²/l	NOUN
hsn-1065	14	32	.	.	PUNCT
hsn-1065	15	1	among	among	ADP
hsn-1065	15	2	cad	cad	PROPN
hsn-1065	15	3	patients	patient	NOUN
hsn-1065	15	4	,	,	PUNCT
hsn-1065	15	5	males	male	NOUN
hsn-1065	15	6	had	have	VERB
hsn-1065	15	7	significantly	significantly	ADV
hsn-1065	15	8	higher	high	ADJ
hsn-1065	15	9	aptt	aptt	ADJ
hsn-1065	15	10	values	value	NOUN
hsn-1065	15	11	(	(	PUNCT
hsn-1065	15	12	65.30	65.30	NUM
hsn-1065	15	13	±	±	NUM
hsn-1065	15	14	14.48	14.48	NUM
hsn-1065	15	15	)	)	PUNCT
hsn-1065	15	16	secs	sec	NOUN
hsn-1065	15	17	than	than	ADP
hsn-1065	15	18	females	female	NOUN
hsn-1065	15	19	(	(	PUNCT
hsn-1065	15	20	48.60	48.60	NUM
hsn-1065	15	21	±	±	NUM
hsn-1065	15	22	8.95	8.95	NUM
hsn-1065	15	23	)	)	PUNCT
hsn-1065	15	24	secs(p	secs(p	NOUN
hsn-1065	15	25	=	=	NOUN
hsn-1065	15	26	0.035	0.035	NUM
hsn-1065	15	27	)	)	PUNCT
hsn-1065	15	28	.	.	PUNCT
hsn-1065	16	1	no	no	DET
hsn-1065	16	2	significant	significant	ADJ
hsn-1065	16	3	gender	gender	NOUN
hsn-1065	16	4	differences	difference	NOUN
hsn-1065	16	5	were	be	AUX
hsn-1065	16	6	observed	observe	VERB
hsn-1065	16	7	in	in	ADP
hsn-1065	16	8	rbc	rbc	PROPN
hsn-1065	16	9	and	and	CCONJ
hsn-1065	16	10	wbc	wbc	PROPN
hsn-1065	16	11	counts	count	NOUN
hsn-1065	16	12	.	.	PUNCT
hsn-1065	17	1	correlation	correlation	NOUN
hsn-1065	17	2	ijo	ijo	PROPN
hsn-1065	17	3	journals	journal	NOUN
hsn-1065	17	4	volume	volume	NOUN
hsn-1065	17	5	08	08	NUM
hsn-1065	18	1	|	|	ADV
hsn-1065	18	2	issue	issue	VERB
hsn-1065	18	3	04	04	NUM
hsn-1065	19	1	|	|	CCONJ
hsn-1065	19	2	april	april	PROPN
hsn-1065	19	3	2025	2025	NUM
hsn-1065	20	1	|	|	ADV
hsn-1065	20	2	https://ijojournals.com/index.php/hsn/index	https://ijojournals.com/index.php/hsn/index	NOUN
hsn-1065	20	3	1	1	NUM
hsn-1065	20	4	ijo	ijo	PROPN
hsn-1065	20	5	international	international	PROPN
hsn-1065	20	6	journal	journal	PROPN
hsn-1065	20	7	of	of	ADP
hsn-1065	20	8	health	health	PROPN
hsn-1065	20	9	sciences	sciences	PROPN
hsn-1065	20	10	and	and	CCONJ
hsn-1065	20	11	nursing	nursing	NOUN
hsn-1065	20	12	(	(	PUNCT
hsn-1065	20	13	issn	issn	PROPN
hsn-1065	20	14	:	:	PUNCT
hsn-1065	20	15	2814	2814	NUM
hsn-1065	20	16	-	-	SYM
hsn-1065	20	17	2098	2098	NUM
hsn-1065	20	18	)	)	PUNCT
hsn-1065	20	19	chinedu	chinedu	NOUN
hsn-1065	20	20	-	-	PUNCT
hsn-1065	20	21	madu	madu	NOUN
hsn-1065	20	22	jane	jane	NOUN
hsn-1065	20	23	u	u	NOUN
hsn-1065	20	24	1	1	NUM
hsn-1065	20	25	*	*	PUNCT
hsn-1065	20	26	https://ijojournals.com/	https://ijojournals.com/	NOUN
hsn-1065	20	27	volume	volume	NOUN
hsn-1065	20	28	08	08	NUM
hsn-1065	20	29	||	||	PROPN
hsn-1065	20	30	issue	issue	NOUN
hsn-1065	20	31	04	04	NUM
hsn-1065	20	32	||	||	NOUN
hsn-1065	20	33	april	april	PROPN
hsn-1065	20	34	,	,	PUNCT
hsn-1065	20	35	2025	2025	NUM
hsn-1065	20	36	||	||	PUNCT
hsn-1065	21	1	“	"	PUNCT
hsn-1065	21	2	studies	study	NOUN
hsn-1065	21	3	on	on	ADP
hsn-1065	21	4	activated	activate	VERB
hsn-1065	21	5	partial	partial	ADJ
hsn-1065	21	6	thromboplastin	thromboplastin	NOUN
hsn-1065	21	7	time	time	NOUN
hsn-1065	21	8	,	,	PUNCT
hsn-1065	21	9	red	red	ADJ
hsn-1065	21	10	and	and	CCONJ
hsn-1065	21	11	white	white	ADJ
hsn-1065	21	12	blood	blood	NOUN
hsn-1065	21	13	cell	cell	NOUN
hsn-1065	21	14	counts	count	NOUN
hsn-1065	21	15	in	in	ADP
hsn-1065	21	16	coronary	coronary	ADJ
hsn-1065	21	17	artery	artery	NOUN
hsn-1065	21	18	disease	disease	NOUN
hsn-1065	21	19	in	in	ADP
hsn-1065	21	20	owerri	owerri	PROPN
hsn-1065	21	21	,	,	PUNCT
hsn-1065	21	22	nigeria	nigeria	PROPN
hsn-1065	21	23	..	..	PUNCT
hsn-1065	21	24	"	"	PUNCT
hsn-1065	21	25	analysis	analysis	NOUN
hsn-1065	21	26	revealed	reveal	VERB
hsn-1065	21	27	insignificant	insignificant	ADJ
hsn-1065	21	28	negative	negative	ADJ
hsn-1065	21	29	correlations	correlation	NOUN
hsn-1065	21	30	of	of	ADP
hsn-1065	21	31	aptt	aptt	NOUN
hsn-1065	21	32	with	with	ADP
hsn-1065	21	33	rbc	rbc	PROPN
hsn-1065	21	34	(	(	PUNCT
hsn-1065	21	35	r	r	NOUN
hsn-1065	21	36	=	=	PUNCT
hsn-1065	21	37	-0.025	-0.025	NOUN
hsn-1065	21	38	,	,	PUNCT
hsn-1065	21	39	p	p	NOUN
hsn-1065	21	40	=	=	NOUN
hsn-1065	21	41	0.897	0.897	NUM
hsn-1065	21	42	)	)	PUNCT
hsn-1065	21	43	,	,	PUNCT
hsn-1065	21	44	and	and	CCONJ
hsn-1065	21	45	wbc(r	wbc(r	PROPN
hsn-1065	21	46	=	=	PUNCT
hsn-1065	21	47	-0.038	-0.038	PROPN
hsn-1065	21	48	,	,	PUNCT
hsn-1065	21	49	p	p	X
hsn-1065	21	50	=	=	NOUN
hsn-1065	21	51	0.843	0.843	NUM
hsn-1065	21	52	)	)	PUNCT
hsn-1065	21	53	.	.	PUNCT
hsn-1065	22	1	conclusion	conclusion	NOUN
hsn-1065	22	2	:	:	PUNCT
hsn-1065	22	3	cad	cad	PROPN
hsn-1065	22	4	patients	patient	NOUN
hsn-1065	22	5	in	in	ADP
hsn-1065	22	6	owerri	owerri	NOUN
hsn-1065	22	7	exhibit	exhibit	VERB
hsn-1065	22	8	significant	significant	ADJ
hsn-1065	22	9	hematological	hematological	ADJ
hsn-1065	22	10	abnormalities	abnormality	NOUN
hsn-1065	22	11	,	,	PUNCT
hsn-1065	22	12	including	include	VERB
hsn-1065	22	13	elevated	elevate	VERB
hsn-1065	22	14	aptt	aptt	ADJ
hsn-1065	22	15	and	and	CCONJ
hsn-1065	22	16	wbc	wbc	ADJ
hsn-1065	22	17	levels	level	NOUN
hsn-1065	22	18	and	and	CCONJ
hsn-1065	22	19	reduced	reduce	VERB
hsn-1065	22	20	rbc	rbc	PROPN
hsn-1065	22	21	counts	count	NOUN
hsn-1065	22	22	.	.	PUNCT
hsn-1065	23	1	although	although	SCONJ
hsn-1065	23	2	gender	gender	NOUN
hsn-1065	23	3	-	-	PUNCT
hsn-1065	23	4	related	relate	VERB
hsn-1065	23	5	variations	variation	NOUN
hsn-1065	23	6	were	be	AUX
hsn-1065	23	7	observed	observe	VERB
hsn-1065	23	8	in	in	ADP
hsn-1065	23	9	aptt	aptt	ADJ
hsn-1065	23	10	,	,	PUNCT
hsn-1065	23	11	no	no	DET
hsn-1065	23	12	significant	significant	ADJ
hsn-1065	23	13	correlations	correlation	NOUN
hsn-1065	23	14	among	among	ADP
hsn-1065	23	15	aptt	aptt	PROPN
hsn-1065	23	16	,	,	PUNCT
hsn-1065	23	17	rbc	rbc	PROPN
hsn-1065	23	18	,	,	PUNCT
hsn-1065	23	19	and	and	CCONJ
hsn-1065	23	20	wbc	wbc	PROPN
hsn-1065	23	21	suggest	suggest	VERB
hsn-1065	23	22	independent	independent	ADJ
hsn-1065	23	23	pathological	pathological	ADJ
hsn-1065	23	24	mechanisms	mechanism	NOUN
hsn-1065	23	25	.	.	PUNCT
hsn-1065	24	1	comprehensive	comprehensive	ADJ
hsn-1065	24	2	hematological	hematological	ADJ
hsn-1065	24	3	assessments	assessment	NOUN
hsn-1065	24	4	should	should	AUX
hsn-1065	24	5	be	be	AUX
hsn-1065	24	6	incorporated	incorporate	VERB
hsn-1065	24	7	into	into	ADP
hsn-1065	24	8	cad	cad	PROPN
hsn-1065	24	9	management	management	NOUN
hsn-1065	24	10	protocols	protocol	NOUN
hsn-1065	24	11	.	.	PUNCT
hsn-1065	25	1	further	further	ADJ
hsn-1065	25	2	studies	study	NOUN
hsn-1065	25	3	arewarranted	arewarrante	VERB
hsn-1065	25	4	to	to	PART
hsn-1065	25	5	explore	explore	VERB
hsn-1065	25	6	the	the	DET
hsn-1065	25	7	underlying	underlying	ADJ
hsn-1065	25	8	mechanisms	mechanism	NOUN
hsn-1065	25	9	of	of	ADP
hsn-1065	25	10	these	these	DET
hsn-1065	25	11	hematological	hematological	ADJ
hsn-1065	25	12	changes	change	NOUN
hsn-1065	25	13	.	.	PUNCT
hsn-1065	26	1	key	key	ADJ
hsn-1065	26	2	words	word	NOUN
hsn-1065	26	3	:	:	PUNCT
hsn-1065	26	4	activted	activte	VERB
hsn-1065	26	5	partial	partial	ADJ
hsn-1065	26	6	thromboplastin	thromboplastin	NOUN
hsn-1065	26	7	time	time	NOUN
hsn-1065	26	8	,	,	PUNCT
hsn-1065	26	9	red	red	ADJ
hsn-1065	26	10	blood	blood	NOUN
hsn-1065	26	11	cell	cell	NOUN
hsn-1065	26	12	,	,	PUNCT
hsn-1065	26	13	white	white	ADJ
hsn-1065	26	14	blood	blood	NOUN
hsn-1065	26	15	cell	cell	NOUN
hsn-1065	26	16	,	,	PUNCT
hsn-1065	26	17	coronary	coronary	ADJ
hsn-1065	26	18	artery	artery	NOUN
hsn-1065	26	19	disease	disease	NOUN
hsn-1065	26	20	.	.	PUNCT
hsn-1065	27	1	1	1	X
hsn-1065	27	2	.	.	X
hsn-1065	27	3	introduction	introduction	NOUN
hsn-1065	27	4	coronary	coronary	ADJ
hsn-1065	27	5	artery	artery	NOUN
hsn-1065	27	6	disease	disease	NOUN
hsn-1065	27	7	(	(	PUNCT
hsn-1065	27	8	cad	cad	NOUN
hsn-1065	27	9	)	)	PUNCT
hsn-1065	27	10	is	be	AUX
hsn-1065	27	11	one	one	NUM
hsn-1065	27	12	of	of	ADP
hsn-1065	27	13	the	the	DET
hsn-1065	27	14	foremost	foremost	ADJ
hsn-1065	27	15	causes	cause	NOUN
hsn-1065	27	16	of	of	ADP
hsn-1065	27	17	morbidity	morbidity	NOUN
hsn-1065	27	18	and	and	CCONJ
hsn-1065	27	19	mortality	mortality	NOUN
hsn-1065	27	20	globally	globally	ADV
hsn-1065	27	21	,	,	PUNCT
hsn-1065	27	22	particularly	particularly	ADV
hsn-1065	27	23	in	in	ADP
hsn-1065	27	24	lowand	lowand	ADJ
hsn-1065	27	25	middle	middle	ADJ
hsn-1065	27	26	-	-	PUNCT
hsn-1065	27	27	income	income	NOUN
hsn-1065	27	28	countries	country	NOUN
hsn-1065	27	29	where	where	SCONJ
hsn-1065	27	30	risk	risk	NOUN
hsn-1065	27	31	factor	factor	NOUN
hsn-1065	27	32	control	control	NOUN
hsn-1065	27	33	is	be	AUX
hsn-1065	27	34	often	often	ADV
hsn-1065	27	35	suboptimal	suboptimal	ADJ
hsn-1065	27	36	[	[	X
hsn-1065	27	37	1	1	NUM
hsn-1065	27	38	]	]	PUNCT
hsn-1065	27	39	.	.	PUNCT
hsn-1065	28	1	although	although	SCONJ
hsn-1065	28	2	the	the	DET
hsn-1065	28	3	classical	classical	ADJ
hsn-1065	28	4	risk	risk	NOUN
hsn-1065	28	5	factors	factor	NOUN
hsn-1065	28	6	such	such	ADJ
hsn-1065	28	7	as	as	ADP
hsn-1065	28	8	hypertension	hypertension	NOUN
hsn-1065	28	9	,	,	PUNCT
hsn-1065	28	10	diabetes	diabetes	NOUN
hsn-1065	28	11	mellitus	mellitus	NOUN
hsn-1065	28	12	,	,	PUNCT
hsn-1065	28	13	dyslipidemia	dyslipidemia	NOUN
hsn-1065	28	14	,	,	PUNCT
hsn-1065	28	15	smoking	smoking	NOUN
hsn-1065	28	16	,	,	PUNCT
hsn-1065	28	17	and	and	CCONJ
hsn-1065	28	18	sedentary	sedentary	ADJ
hsn-1065	28	19	lifestyle	lifestyle	NOUN
hsn-1065	28	20	are	be	AUX
hsn-1065	28	21	well	well	ADV
hsn-1065	28	22	established	establish	VERB
hsn-1065	28	23	,	,	PUNCT
hsn-1065	28	24	growing	grow	VERB
hsn-1065	28	25	evidence	evidence	NOUN
hsn-1065	28	26	suggests	suggest	VERB
hsn-1065	28	27	that	that	SCONJ
hsn-1065	28	28	hematological	hematological	ADJ
hsn-1065	28	29	and	and	CCONJ
hsn-1065	28	30	haemostatic	haemostatic	ADJ
hsn-1065	28	31	parameters	parameter	NOUN
hsn-1065	28	32	significantly	significantly	ADV
hsn-1065	28	33	influence	influence	VERB
hsn-1065	28	34	the	the	DET
hsn-1065	28	35	pathogenesis	pathogenesis	NOUN
hsn-1065	28	36	and	and	CCONJ
hsn-1065	28	37	prognosis	prognosis	NOUN
hsn-1065	28	38	of	of	ADP
hsn-1065	28	39	cad	cad	PROPN
hsn-1065	29	1	[	[	X
hsn-1065	29	2	2	2	NUM
hsn-1065	29	3	]	]	PUNCT
hsn-1065	29	4	.	.	PUNCT
hsn-1065	30	1	activated	activate	VERB
hsn-1065	30	2	partial	partial	ADJ
hsn-1065	30	3	thromboplastin	thromboplastin	NOUN
hsn-1065	30	4	time	time	NOUN
hsn-1065	30	5	(	(	PUNCT
hsn-1065	30	6	aptt	aptt	NOUN
hsn-1065	30	7	)	)	PUNCT
hsn-1065	30	8	assesses	assess	VERB
hsn-1065	30	9	the	the	DET
hsn-1065	30	10	intrinsic	intrinsic	ADJ
hsn-1065	30	11	and	and	CCONJ
hsn-1065	30	12	common	common	ADJ
hsn-1065	30	13	coagulation	coagulation	NOUN
hsn-1065	30	14	pathways	pathway	NOUN
hsn-1065	30	15	and	and	CCONJ
hsn-1065	30	16	can	can	AUX
hsn-1065	30	17	reflect	reflect	VERB
hsn-1065	30	18	hypercoagulable	hypercoagulable	ADJ
hsn-1065	30	19	or	or	CCONJ
hsn-1065	30	20	hypocoagulable	hypocoagulable	ADJ
hsn-1065	30	21	states	state	NOUN
hsn-1065	30	22	depending	depend	VERB
hsn-1065	30	23	on	on	ADP
hsn-1065	30	24	the	the	DET
hsn-1065	30	25	context	context	NOUN
hsn-1065	31	1	[	[	X
hsn-1065	31	2	3	3	NUM
hsn-1065	31	3	]	]	PUNCT
hsn-1065	31	4	.	.	PUNCT
hsn-1065	32	1	in	in	ADP
hsn-1065	32	2	cad	cad	PROPN
hsn-1065	32	3	,	,	PUNCT
hsn-1065	32	4	alterations	alteration	NOUN
hsn-1065	32	5	in	in	ADP
hsn-1065	32	6	coagulation	coagulation	NOUN
hsn-1065	32	7	markers	marker	NOUN
hsn-1065	32	8	may	may	AUX
hsn-1065	32	9	signal	signal	VERB
hsn-1065	32	10	endothelial	endothelial	ADJ
hsn-1065	32	11	dysfunction	dysfunction	NOUN
hsn-1065	32	12	or	or	CCONJ
hsn-1065	32	13	thrombosis	thrombosis	NOUN
hsn-1065	32	14	risk	risk	NOUN
hsn-1065	32	15	.	.	PUNCT
hsn-1065	33	1	additionally	additionally	ADV
hsn-1065	33	2	,	,	PUNCT
hsn-1065	33	3	elevated	elevated	ADJ
hsn-1065	33	4	white	white	ADJ
hsn-1065	33	5	blood	blood	NOUN
hsn-1065	33	6	cell	cell	NOUN
hsn-1065	33	7	(	(	PUNCT
hsn-1065	33	8	wbc	wbc	PROPN
hsn-1065	33	9	)	)	PUNCT
hsn-1065	33	10	count	count	NOUN
hsn-1065	33	11	is	be	AUX
hsn-1065	33	12	a	a	DET
hsn-1065	33	13	known	know	VERB
hsn-1065	33	14	marker	marker	NOUN
hsn-1065	33	15	of	of	ADP
hsn-1065	33	16	systemic	systemic	ADJ
hsn-1065	33	17	inflammation	inflammation	NOUN
hsn-1065	33	18	and	and	CCONJ
hsn-1065	33	19	has	have	AUX
hsn-1065	33	20	been	be	AUX
hsn-1065	33	21	associated	associate	VERB
hsn-1065	33	22	with	with	ADP
hsn-1065	33	23	plaque	plaque	NOUN
hsn-1065	33	24	instability	instability	NOUN
hsn-1065	33	25	and	and	CCONJ
hsn-1065	33	26	adverse	adverse	ADJ
hsn-1065	33	27	cardiac	cardiac	ADJ
hsn-1065	33	28	events	event	NOUN
hsn-1065	33	29	[	[	X
hsn-1065	33	30	4	4	NUM
hsn-1065	33	31	]	]	PUNCT
hsn-1065	33	32	.	.	PUNCT
hsn-1065	34	1	conversely	conversely	ADV
hsn-1065	34	2	,	,	PUNCT
hsn-1065	34	3	reduced	reduce	VERB
hsn-1065	34	4	red	red	ADJ
hsn-1065	34	5	blood	blood	NOUN
hsn-1065	34	6	cell	cell	NOUN
hsn-1065	34	7	(	(	PUNCT
hsn-1065	34	8	rbc	rbc	PROPN
hsn-1065	34	9	)	)	PUNCT
hsn-1065	34	10	count	count	NOUN
hsn-1065	34	11	may	may	AUX
hsn-1065	34	12	impair	impair	VERB
hsn-1065	34	13	oxygen	oxygen	NOUN
hsn-1065	34	14	delivery	delivery	NOUN
hsn-1065	34	15	to	to	ADP
hsn-1065	34	16	ischemic	ischemic	ADJ
hsn-1065	34	17	myocardial	myocardial	ADJ
hsn-1065	34	18	tissue	tissue	NOUN
hsn-1065	34	19	,	,	PUNCT
hsn-1065	34	20	exacerbating	exacerbate	VERB
hsn-1065	34	21	tissue	tissue	NOUN
hsn-1065	34	22	damage	damage	NOUN
hsn-1065	34	23	[	[	X
hsn-1065	34	24	5	5	NUM
hsn-1065	34	25	]	]	PUNCT
hsn-1065	34	26	gender	gender	NOUN
hsn-1065	34	27	-	-	PUNCT
hsn-1065	34	28	based	base	VERB
hsn-1065	34	29	differences	difference	NOUN
hsn-1065	34	30	in	in	ADP
hsn-1065	34	31	hematological	hematological	ADJ
hsn-1065	34	32	and	and	CCONJ
hsn-1065	34	33	coagulation	coagulation	NOUN
hsn-1065	34	34	profiles	profile	NOUN
hsn-1065	34	35	in	in	ADP
hsn-1065	34	36	cad	cad	PROPN
hsn-1065	34	37	patients	patient	NOUN
hsn-1065	34	38	have	have	AUX
hsn-1065	34	39	also	also	ADV
hsn-1065	34	40	been	be	AUX
hsn-1065	34	41	reported	report	VERB
hsn-1065	34	42	.	.	PUNCT
hsn-1065	35	1	females	female	NOUN
hsn-1065	35	2	may	may	AUX
hsn-1065	35	3	exhibit	exhibit	VERB
hsn-1065	35	4	elevated	elevated	ADJ
hsn-1065	35	5	coagulation	coagulation	NOUN
hsn-1065	35	6	markers	marker	NOUN
hsn-1065	35	7	and	and	CCONJ
hsn-1065	35	8	inflammatory	inflammatory	ADJ
hsn-1065	35	9	indices	index	NOUN
hsn-1065	35	10	compared	compare	VERB
hsn-1065	35	11	to	to	ADP
hsn-1065	35	12	males	male	NOUN
hsn-1065	35	13	,	,	PUNCT
hsn-1065	35	14	potentially	potentially	ADV
hsn-1065	35	15	influencing	influence	VERB
hsn-1065	35	16	disease	disease	NOUN
hsn-1065	35	17	progression	progression	NOUN
hsn-1065	35	18	and	and	CCONJ
hsn-1065	35	19	therapeutic	therapeutic	ADJ
hsn-1065	35	20	outcomes	outcome	NOUN
hsn-1065	36	1	[	[	X
hsn-1065	36	2	6	6	NUM
hsn-1065	36	3	]	]	PUNCT
hsn-1065	36	4	.	.	PUNCT
hsn-1065	37	1	these	these	DET
hsn-1065	37	2	gender	gender	NOUN
hsn-1065	37	3	-	-	PUNCT
hsn-1065	37	4	based	base	VERB
hsn-1065	37	5	disparities	disparity	NOUN
hsn-1065	37	6	warrant	warrant	VERB
hsn-1065	37	7	investigation	investigation	NOUN
hsn-1065	37	8	in	in	ADP
hsn-1065	37	9	specific	specific	ADJ
hsn-1065	37	10	populations	population	NOUN
hsn-1065	37	11	,	,	PUNCT
hsn-1065	37	12	including	include	VERB
hsn-1065	37	13	nigerians	nigerian	NOUN
hsn-1065	37	14	,	,	PUNCT
hsn-1065	37	15	where	where	SCONJ
hsn-1065	37	16	there	there	PRON
hsn-1065	37	17	is	be	VERB
hsn-1065	37	18	a	a	DET
hsn-1065	37	19	paucity	paucity	NOUN
hsn-1065	37	20	of	of	ADP
hsn-1065	37	21	localized	localized	ADJ
hsn-1065	37	22	data	datum	NOUN
hsn-1065	37	23	.	.	PUNCT
hsn-1065	38	1	this	this	DET
hsn-1065	38	2	study	study	NOUN
hsn-1065	38	3	ijo	ijo	PROPN
hsn-1065	38	4	journals	journal	NOUN
hsn-1065	38	5	volume	volume	NOUN
hsn-1065	38	6	08	08	NUM
hsn-1065	39	1	|	|	ADV
hsn-1065	39	2	issue	issue	VERB
hsn-1065	39	3	04	04	NUM
hsn-1065	40	1	|	|	CCONJ
hsn-1065	40	2	april	april	PROPN
hsn-1065	40	3	2025	2025	NUM
hsn-1065	41	1	|	|	ADV
hsn-1065	41	2	https://ijojournals.com/index.php/hsn/index	https://ijojournals.com/index.php/hsn/index	NOUN
hsn-1065	41	3	2	2	NUM
hsn-1065	41	4	ijo	ijo	PROPN
hsn-1065	41	5	international	international	ADJ
hsn-1065	41	6	journal	journal	PROPN
hsn-1065	41	7	of	of	ADP
hsn-1065	41	8	health	health	PROPN
hsn-1065	41	9	sciences	sciences	PROPN
hsn-1065	41	10	and	and	CCONJ
hsn-1065	41	11	nursing	nursing	NOUN
hsn-1065	41	12	(	(	PUNCT
hsn-1065	41	13	issn	issn	PROPN
hsn-1065	41	14	:	:	PUNCT
hsn-1065	41	15	2814	2814	NUM
hsn-1065	41	16	-	-	SYM
hsn-1065	41	17	2098	2098	NUM
hsn-1065	41	18	)	)	PUNCT
hsn-1065	41	19	chinedu	chinedu	NOUN
hsn-1065	41	20	-	-	PUNCT
hsn-1065	41	21	madu	madu	NOUN
hsn-1065	41	22	jane	jane	NOUN
hsn-1065	41	23	u	u	NOUN
hsn-1065	41	24	1	1	NUM
hsn-1065	41	25	*	*	PUNCT
hsn-1065	41	26	https://ijojournals.com/	https://ijojournals.com/	NOUN
hsn-1065	41	27	volume	volume	NOUN
hsn-1065	41	28	08	08	NUM
hsn-1065	41	29	||	||	PROPN
hsn-1065	41	30	issue	issue	NOUN
hsn-1065	41	31	04	04	NUM
hsn-1065	41	32	||	||	NOUN
hsn-1065	41	33	april	april	PROPN
hsn-1065	41	34	,	,	PUNCT
hsn-1065	41	35	2025	2025	NUM
hsn-1065	41	36	||	||	PUNCT
hsn-1065	42	1	“	"	PUNCT
hsn-1065	42	2	studies	study	NOUN
hsn-1065	42	3	on	on	ADP
hsn-1065	42	4	activated	activate	VERB
hsn-1065	42	5	partial	partial	ADJ
hsn-1065	42	6	thromboplastin	thromboplastin	NOUN
hsn-1065	42	7	time	time	NOUN
hsn-1065	42	8	,	,	PUNCT
hsn-1065	42	9	red	red	ADJ
hsn-1065	42	10	and	and	CCONJ
hsn-1065	42	11	white	white	ADJ
hsn-1065	42	12	blood	blood	NOUN
hsn-1065	42	13	cell	cell	NOUN
hsn-1065	42	14	counts	count	NOUN
hsn-1065	42	15	in	in	ADP
hsn-1065	42	16	coronary	coronary	ADJ
hsn-1065	42	17	artery	artery	NOUN
hsn-1065	42	18	disease	disease	NOUN
hsn-1065	42	19	in	in	ADP
hsn-1065	42	20	owerri	owerri	PROPN
hsn-1065	42	21	,	,	PUNCT
hsn-1065	42	22	nigeria	nigeria	PROPN
hsn-1065	42	23	..	..	PUNCT
hsn-1065	42	24	"	"	PUNCT
hsn-1065	42	25	aims	aim	VERB
hsn-1065	42	26	to	to	PART
hsn-1065	42	27	evaluate	evaluate	VERB
hsn-1065	42	28	the	the	DET
hsn-1065	42	29	levels	level	NOUN
hsn-1065	42	30	of	of	ADP
hsn-1065	42	31	aptt	aptt	PROPN
hsn-1065	42	32	,	,	PUNCT
hsn-1065	42	33	rbc	rbc	PROPN
hsn-1065	42	34	,	,	PUNCT
hsn-1065	42	35	and	and	CCONJ
hsn-1065	42	36	wbc	wbc	PROPN
hsn-1065	42	37	in	in	ADP
hsn-1065	42	38	cad	cad	PROPN
hsn-1065	42	39	patients	patient	NOUN
hsn-1065	42	40	in	in	ADP
hsn-1065	42	41	owerri	owerri	PROPN
hsn-1065	42	42	,	,	PUNCT
hsn-1065	42	43	nigeria	nigeria	PROPN
hsn-1065	42	44	,	,	PUNCT
hsn-1065	42	45	and	and	CCONJ
hsn-1065	42	46	to	to	PART
hsn-1065	42	47	assess	assess	VERB
hsn-1065	42	48	gender	gender	NOUN
hsn-1065	42	49	-	-	PUNCT
hsn-1065	42	50	based	base	VERB
hsn-1065	42	51	differences	difference	NOUN
hsn-1065	42	52	in	in	ADP
hsn-1065	42	53	these	these	DET
hsn-1065	42	54	parameters	parameter	NOUN
hsn-1065	42	55	.2	.2	NUM
hsn-1065	42	56	.	.	PUNCT
hsn-1065	43	1	materials	material	NOUN
hsn-1065	43	2	and	and	CCONJ
hsn-1065	43	3	methods	method	NOUN
hsn-1065	43	4	2.1	2.1	NUM
hsn-1065	43	5	study	study	NOUN
hsn-1065	43	6	area	area	NOUN
hsn-1065	43	7	the	the	DET
hsn-1065	43	8	study	study	NOUN
hsn-1065	43	9	was	be	AUX
hsn-1065	43	10	conducted	conduct	VERB
hsn-1065	43	11	at	at	ADP
hsn-1065	43	12	federal	federal	ADJ
hsn-1065	43	13	university	university	PROPN
hsn-1065	43	14	teaching	teaching	NOUN
hsn-1065	43	15	hospital	hospital	NOUN
hsn-1065	43	16	,	,	PUNCT
hsn-1065	43	17	owerri	owerri	PROPN
hsn-1065	43	18	,	,	PUNCT
hsn-1065	43	19	nigeria	nigeria	PROPN
hsn-1065	43	20	.	.	PUNCT
hsn-1065	44	1	2.2	2.2	NUM
hsn-1065	44	2	study	study	NOUN
hsn-1065	44	3	design	design	NOUN
hsn-1065	44	4	this	this	DET
hsn-1065	44	5	study	study	NOUN
hsn-1065	44	6	employed	employ	VERB
hsn-1065	44	7	a	a	DET
hsn-1065	44	8	cross	cross	ADJ
hsn-1065	44	9	-	-	ADJ
hsn-1065	44	10	sectional	sectional	ADJ
hsn-1065	44	11	analytical	analytical	ADJ
hsn-1065	44	12	design	design	NOUN
hsn-1065	44	13	to	to	PART
hsn-1065	44	14	investigate	investigate	VERB
hsn-1065	44	15	selected	select	VERB
hsn-1065	44	16	hematological	hematological	ADJ
hsn-1065	44	17	and	and	CCONJ
hsn-1065	44	18	haemostatic	haemostatic	ADJ
hsn-1065	44	19	parameters	parameter	NOUN
hsn-1065	44	20	—	—	PUNCT
hsn-1065	44	21	namely	namely	ADV
hsn-1065	44	22	activated	activate	VERB
hsn-1065	44	23	partial	partial	ADJ
hsn-1065	44	24	thromboplastin	thromboplastin	NOUN
hsn-1065	44	25	time	time	NOUN
hsn-1065	44	26	(	(	PUNCT
hsn-1065	44	27	aptt	aptt	NOUN
hsn-1065	44	28	)	)	PUNCT
hsn-1065	44	29	,	,	PUNCT
hsn-1065	44	30	red	red	ADJ
hsn-1065	44	31	blood	blood	NOUN
hsn-1065	44	32	cell	cell	NOUN
hsn-1065	44	33	(	(	PUNCT
hsn-1065	44	34	rbc	rbc	PROPN
hsn-1065	44	35	)	)	PUNCT
hsn-1065	44	36	count	count	NOUN
hsn-1065	44	37	,	,	PUNCT
hsn-1065	44	38	and	and	CCONJ
hsn-1065	44	39	white	white	ADJ
hsn-1065	44	40	blood	blood	NOUN
hsn-1065	44	41	cell	cell	NOUN
hsn-1065	44	42	(	(	PUNCT
hsn-1065	44	43	wbc	wbc	PROPN
hsn-1065	44	44	)	)	PUNCT
hsn-1065	44	45	count	count	NOUN
hsn-1065	44	46	—	—	PUNCT
hsn-1065	44	47	in	in	ADP
hsn-1065	44	48	patients	patient	NOUN
hsn-1065	44	49	diagnosed	diagnose	VERB
hsn-1065	44	50	with	with	ADP
hsn-1065	44	51	coronary	coronary	ADJ
hsn-1065	44	52	artery	artery	NOUN
hsn-1065	44	53	disease	disease	NOUN
hsn-1065	44	54	(	(	PUNCT
hsn-1065	44	55	cad	cad	NOUN
hsn-1065	44	56	)	)	PUNCT
hsn-1065	44	57	compared	compare	VERB
hsn-1065	44	58	to	to	ADP
hsn-1065	44	59	healthy	healthy	ADJ
hsn-1065	44	60	age	age	NOUN
hsn-1065	44	61	-	-	PUNCT
hsn-1065	44	62	matched	match	VERB
hsn-1065	44	63	controls	control	NOUN
hsn-1065	44	64	.	.	PUNCT
hsn-1065	45	1	2.3method	2.3method	NUM
hsn-1065	45	2	of	of	ADP
hsn-1065	45	3	recruitment	recruitment	NOUN
hsn-1065	45	4	a	a	DET
hsn-1065	45	5	total	total	NOUN
hsn-1065	45	6	of	of	ADP
hsn-1065	45	7	60	60	NUM
hsn-1065	45	8	participants	participant	NOUN
hsn-1065	45	9	were	be	AUX
hsn-1065	45	10	recruited	recruit	VERB
hsn-1065	45	11	for	for	ADP
hsn-1065	45	12	the	the	DET
hsn-1065	45	13	study	study	NOUN
hsn-1065	45	14	.	.	PUNCT
hsn-1065	46	1	thirty	thirty	NUM
hsn-1065	46	2	(	(	PUNCT
hsn-1065	46	3	30	30	NUM
hsn-1065	46	4	)	)	PUNCT
hsn-1065	46	5	patients	patient	NOUN
hsn-1065	46	6	diagnosed	diagnose	VERB
hsn-1065	46	7	with	with	ADP
hsn-1065	46	8	coronary	coronary	ADJ
hsn-1065	46	9	artery	artery	NOUN
hsn-1065	46	10	disease	disease	NOUN
hsn-1065	46	11	(	(	PUNCT
hsn-1065	46	12	19	19	NUM
hsn-1065	46	13	males	male	NOUN
hsn-1065	46	14	and	and	CCONJ
hsn-1065	46	15	11	11	NUM
hsn-1065	46	16	females	female	NOUN
hsn-1065	46	17	)	)	PUNCT
hsn-1065	46	18	were	be	AUX
hsn-1065	46	19	selected	select	VERB
hsn-1065	46	20	from	from	ADP
hsn-1065	46	21	the	the	DET
hsn-1065	46	22	cardiology	cardiology	NOUN
hsn-1065	46	23	unit	unit	NOUN
hsn-1065	46	24	of	of	ADP
hsn-1065	46	25	a	a	DET
hsn-1065	46	26	tertiary	tertiary	ADJ
hsn-1065	46	27	hospital	hospital	NOUN
hsn-1065	46	28	in	in	ADP
hsn-1065	46	29	owerri	owerri	PROPN
hsn-1065	46	30	,	,	PUNCT
hsn-1065	46	31	nigeria	nigeria	PROPN
hsn-1065	46	32	.	.	PUNCT
hsn-1065	47	1	thirty	thirty	NUM
hsn-1065	47	2	(	(	PUNCT
hsn-1065	47	3	30	30	NUM
hsn-1065	47	4	)	)	PUNCT
hsn-1065	47	5	ageand	ageand	NOUN
hsn-1065	47	6	sex	sex	NOUN
hsn-1065	47	7	-	-	PUNCT
hsn-1065	47	8	matched	match	VERB
hsn-1065	47	9	apparently	apparently	ADV
hsn-1065	47	10	healthy	healthy	ADJ
hsn-1065	47	11	individuals	individual	NOUN
hsn-1065	47	12	without	without	ADP
hsn-1065	47	13	a	a	DET
hsn-1065	47	14	history	history	NOUN
hsn-1065	47	15	of	of	ADP
hsn-1065	47	16	cardiovascular	cardiovascular	ADJ
hsn-1065	47	17	disease	disease	NOUN
hsn-1065	47	18	served	serve	VERB
hsn-1065	47	19	as	as	ADP
hsn-1065	47	20	the	the	DET
hsn-1065	47	21	control	control	NOUN
hsn-1065	47	22	group	group	NOUN
hsn-1065	47	23	.	.	PUNCT
hsn-1065	48	1	participants	participant	NOUN
hsn-1065	48	2	were	be	AUX
hsn-1065	48	3	recruited	recruit	VERB
hsn-1065	48	4	using	use	VERB
hsn-1065	48	5	purposive	purposive	NOUN
hsn-1065	48	6	sampling	sampling	NOUN
hsn-1065	48	7	based	base	VERB
hsn-1065	48	8	on	on	ADP
hsn-1065	48	9	inclusion	inclusion	NOUN
hsn-1065	48	10	and	and	CCONJ
hsn-1065	48	11	exclusion	exclusion	NOUN
hsn-1065	48	12	criteria	criterion	NOUN
hsn-1065	48	13	.	.	PUNCT
hsn-1065	49	1	inclusion	inclusion	NOUN
hsn-1065	49	2	criteria	criterion	NOUN
hsn-1065	49	3	for	for	ADP
hsn-1065	49	4	cad	cad	PROPN
hsn-1065	49	5	patients	patient	NOUN
hsn-1065	49	6	included	include	VERB
hsn-1065	49	7	clinical	clinical	ADJ
hsn-1065	49	8	diagnosis	diagnosis	NOUN
hsn-1065	49	9	of	of	ADP
hsn-1065	49	10	cad	cad	PROPN
hsn-1065	49	11	confirmed	confirm	VERB
hsn-1065	49	12	by	by	ADP
hsn-1065	49	13	a	a	DET
hsn-1065	49	14	cardiologist	cardiologist	NOUN
hsn-1065	49	15	.	.	PUNCT
hsn-1065	50	1	individuals	individual	NOUN
hsn-1065	50	2	with	with	ADP
hsn-1065	50	3	other	other	ADJ
hsn-1065	50	4	comorbid	comorbid	NOUN
hsn-1065	50	5	conditions	condition	NOUN
hsn-1065	50	6	such	such	ADJ
hsn-1065	50	7	as	as	ADP
hsn-1065	50	8	diabetes	diabetes	NOUN
hsn-1065	50	9	,	,	PUNCT
hsn-1065	50	10	malignancies	malignancy	NOUN
hsn-1065	50	11	,	,	PUNCT
hsn-1065	50	12	or	or	CCONJ
hsn-1065	50	13	hematological	hematological	ADJ
hsn-1065	50	14	disorders	disorder	NOUN
hsn-1065	50	15	were	be	AUX
hsn-1065	50	16	excluded	exclude	VERB
hsn-1065	50	17	.	.	PUNCT
hsn-1065	51	1	2.4	2.4	NUM
hsn-1065	51	2	ethical	ethical	ADJ
hsn-1065	51	3	approval	approval	NOUN
hsn-1065	51	4	ethical	ethical	ADJ
hsn-1065	51	5	approval	approval	NOUN
hsn-1065	51	6	for	for	ADP
hsn-1065	51	7	the	the	DET
hsn-1065	51	8	study	study	NOUN
hsn-1065	51	9	was	be	AUX
hsn-1065	51	10	obtained	obtain	VERB
hsn-1065	51	11	from	from	ADP
hsn-1065	51	12	the	the	DET
hsn-1065	51	13	ethics	ethic	NOUN
hsn-1065	51	14	and	and	CCONJ
hsn-1065	51	15	research	research	NOUN
hsn-1065	51	16	committee	committee	NOUN
hsn-1065	51	17	of	of	ADP
hsn-1065	51	18	the	the	DET
hsn-1065	51	19	[	[	X
hsn-1065	51	20	name	name	NOUN
hsn-1065	51	21	of	of	ADP
hsn-1065	51	22	hospital	hospital	NOUN
hsn-1065	51	23	or	or	CCONJ
hsn-1065	51	24	institution	institution	NOUN
hsn-1065	51	25	]	]	PUNCT
hsn-1065	51	26	(	(	PUNCT
hsn-1065	51	27	approval	approval	NOUN
hsn-1065	51	28	number	number	NOUN
hsn-1065	51	29	:	:	PUNCT
hsn-1065	52	1	[	[	X
hsn-1065	52	2	insert	insert	ADJ
hsn-1065	52	3	number	number	NOUN
hsn-1065	52	4	]	]	PUNCT
hsn-1065	52	5	)	)	PUNCT
hsn-1065	52	6	.	.	PUNCT
hsn-1065	53	1	informed	informed	ADJ
hsn-1065	53	2	consent	consent	NOUN
hsn-1065	53	3	was	be	AUX
hsn-1065	53	4	obtained	obtain	VERB
hsn-1065	53	5	from	from	ADP
hsn-1065	53	6	all	all	DET
hsn-1065	53	7	participants	participant	NOUN
hsn-1065	53	8	prior	prior	ADV
hsn-1065	53	9	to	to	ADP
hsn-1065	53	10	sample	sample	NOUN
hsn-1065	53	11	collection	collection	NOUN
hsn-1065	53	12	.	.	PUNCT
hsn-1065	54	1	confidentiality	confidentiality	NOUN
hsn-1065	54	2	and	and	CCONJ
hsn-1065	54	3	anonymity	anonymity	NOUN
hsn-1065	54	4	were	be	AUX
hsn-1065	54	5	maintained	maintain	VERB
hsn-1065	54	6	throughout	throughout	ADP
hsn-1065	54	7	the	the	DET
hsn-1065	54	8	study	study	NOUN
hsn-1065	54	9	.	.	PUNCT
hsn-1065	55	1	ijo	ijo	PROPN
hsn-1065	55	2	journals	journal	NOUN
hsn-1065	55	3	volume	volume	NOUN
hsn-1065	55	4	08	08	NUM
hsn-1065	56	1	|	|	ADV
hsn-1065	56	2	issue	issue	VERB
hsn-1065	56	3	04	04	NUM
hsn-1065	57	1	|	|	CCONJ
hsn-1065	57	2	april	april	PROPN
hsn-1065	57	3	2025	2025	NUM
hsn-1065	57	4	|	|	ADV
hsn-1065	57	5	https://ijojournals.com/index.php/hsn/index	https://ijojournals.com/index.php/hsn/index	NOUN
hsn-1065	57	6	3	3	NUM
hsn-1065	57	7	ijo	ijo	PROPN
hsn-1065	57	8	international	international	PROPN
hsn-1065	57	9	journal	journal	PROPN
hsn-1065	57	10	of	of	ADP
hsn-1065	57	11	health	health	PROPN
hsn-1065	57	12	sciences	sciences	PROPN
hsn-1065	57	13	and	and	CCONJ
hsn-1065	57	14	nursing	nursing	NOUN
hsn-1065	57	15	(	(	PUNCT
hsn-1065	57	16	issn	issn	PROPN
hsn-1065	57	17	:	:	PUNCT
hsn-1065	57	18	2814	2814	NUM
hsn-1065	57	19	-	-	SYM
hsn-1065	57	20	2098	2098	NUM
hsn-1065	57	21	)	)	PUNCT
hsn-1065	57	22	chinedu	chinedu	NOUN
hsn-1065	57	23	-	-	PUNCT
hsn-1065	57	24	madu	madu	NOUN
hsn-1065	57	25	jane	jane	NOUN
hsn-1065	57	26	u	u	NOUN
hsn-1065	58	1	1	1	NUM
hsn-1065	58	2	*	*	PUNCT
hsn-1065	58	3	https://ijojournals.com/	https://ijojournals.com/	NOUN
hsn-1065	58	4	volume	volume	NOUN
hsn-1065	58	5	08	08	NUM
hsn-1065	58	6	||	||	PROPN
hsn-1065	58	7	issue	issue	NOUN
hsn-1065	58	8	04	04	NUM
hsn-1065	58	9	||	||	NOUN
hsn-1065	58	10	april	april	PROPN
hsn-1065	58	11	,	,	PUNCT
hsn-1065	58	12	2025	2025	NUM
hsn-1065	58	13	||	||	PUNCT
hsn-1065	59	1	“	"	PUNCT
hsn-1065	59	2	studies	study	NOUN
hsn-1065	59	3	on	on	ADP
hsn-1065	59	4	activated	activate	VERB
hsn-1065	59	5	partial	partial	ADJ
hsn-1065	59	6	thromboplastin	thromboplastin	NOUN
hsn-1065	59	7	time	time	NOUN
hsn-1065	59	8	,	,	PUNCT
hsn-1065	59	9	red	red	ADJ
hsn-1065	59	10	and	and	CCONJ
hsn-1065	59	11	white	white	ADJ
hsn-1065	59	12	blood	blood	NOUN
hsn-1065	59	13	cell	cell	NOUN
hsn-1065	59	14	counts	count	NOUN
hsn-1065	59	15	in	in	ADP
hsn-1065	59	16	coronary	coronary	ADJ
hsn-1065	59	17	artery	artery	NOUN
hsn-1065	59	18	disease	disease	NOUN
hsn-1065	59	19	in	in	ADP
hsn-1065	59	20	owerri	owerri	PROPN
hsn-1065	59	21	,	,	PUNCT
hsn-1065	59	22	nigeria	nigeria	PROPN
hsn-1065	59	23	..	..	PUNCT
hsn-1065	59	24	"	"	PUNCT
hsn-1065	59	25	2.5	2.5	NUM
hsn-1065	59	26	laboratory	laboratory	NOUN
hsn-1065	59	27	analysis	analysis	NOUN
hsn-1065	59	28	venous	venous	ADJ
hsn-1065	59	29	blood	blood	NOUN
hsn-1065	59	30	samples	sample	NOUN
hsn-1065	59	31	(	(	PUNCT
hsn-1065	59	32	5	5	NUM
hsn-1065	59	33	ml	ml	NOUN
hsn-1065	59	34	)	)	PUNCT
hsn-1065	59	35	were	be	AUX
hsn-1065	59	36	collected	collect	VERB
hsn-1065	59	37	aseptically	aseptically	ADV
hsn-1065	59	38	from	from	ADP
hsn-1065	59	39	each	each	DET
hsn-1065	59	40	participant	participant	NOUN
hsn-1065	59	41	.	.	PUNCT
hsn-1065	60	1	three	three	NUM
hsn-1065	60	2	milliliters	milliliter	NOUN
hsn-1065	60	3	(	(	PUNCT
hsn-1065	60	4	3	3	NUM
hsn-1065	60	5	ml	ml	NOUN
hsn-1065	60	6	)	)	PUNCT
hsn-1065	60	7	of	of	ADP
hsn-1065	60	8	the	the	DET
hsn-1065	60	9	blood	blood	NOUN
hsn-1065	60	10	were	be	AUX
hsn-1065	60	11	dispensed	dispense	VERB
hsn-1065	60	12	into	into	ADP
hsn-1065	60	13	ethylenediaminetetraacetic	ethylenediaminetetraacetic	ADJ
hsn-1065	60	14	acid	acid	NOUN
hsn-1065	60	15	(	(	PUNCT
hsn-1065	60	16	edta	edta	NOUN
hsn-1065	60	17	)	)	PUNCT
hsn-1065	60	18	tubes	tube	NOUN
hsn-1065	60	19	for	for	ADP
hsn-1065	60	20	hematological	hematological	ADJ
hsn-1065	60	21	analysis	analysis	NOUN
hsn-1065	60	22	.	.	PUNCT
hsn-1065	61	1	the	the	DET
hsn-1065	61	2	remaining	remain	VERB
hsn-1065	61	3	2	2	NUM
hsn-1065	61	4	ml	ml	NOUN
hsn-1065	61	5	was	be	AUX
hsn-1065	61	6	used	use	VERB
hsn-1065	61	7	for	for	ADP
hsn-1065	61	8	haemostatic	haemostatic	ADJ
hsn-1065	61	9	analysis	analysis	NOUN
hsn-1065	61	10	.	.	PUNCT
hsn-1065	62	1	hematological	hematological	ADJ
hsn-1065	62	2	parameters	parameter	NOUN
hsn-1065	62	3	,	,	PUNCT
hsn-1065	62	4	including	include	VERB
hsn-1065	62	5	rbc	rbc	PROPN
hsn-1065	62	6	and	and	CCONJ
hsn-1065	62	7	wbc	wbc	PROPN
hsn-1065	62	8	counts	count	NOUN
hsn-1065	62	9	,	,	PUNCT
hsn-1065	62	10	were	be	AUX
hsn-1065	62	11	measured	measure	VERB
hsn-1065	62	12	using	use	VERB
hsn-1065	62	13	a	a	DET
hsn-1065	62	14	fully	fully	ADV
hsn-1065	62	15	automated	automate	VERB
hsn-1065	62	16	hematology	hematology	NOUN
hsn-1065	62	17	analyzer	analyzer	NOUN
hsn-1065	62	18	.	.	PUNCT
hsn-1065	63	1	aptt	aptt	PROPN
hsn-1065	63	2	was	be	AUX
hsn-1065	63	3	determined	determine	VERB
hsn-1065	63	4	using	use	VERB
hsn-1065	63	5	a	a	DET
hsn-1065	63	6	standard	standard	ADJ
hsn-1065	63	7	coagulometer	coagulometer	NOUN
hsn-1065	63	8	and	and	CCONJ
hsn-1065	63	9	commercial	commercial	ADJ
hsn-1065	63	10	reagents	reagent	NOUN
hsn-1065	63	11	according	accord	VERB
hsn-1065	63	12	to	to	ADP
hsn-1065	63	13	the	the	DET
hsn-1065	63	14	manufacturer	manufacturer	NOUN
hsn-1065	63	15	’s	’s	PART
hsn-1065	63	16	instructions	instruction	NOUN
hsn-1065	63	17	.	.	PUNCT
hsn-1065	64	1	2.6	2.6	NUM
hsn-1065	64	2	statistical	statistical	ADJ
hsn-1065	64	3	analysis	analysis	NOUN
hsn-1065	64	4	data	datum	NOUN
hsn-1065	64	5	were	be	AUX
hsn-1065	64	6	analyzed	analyze	VERB
hsn-1065	64	7	using	use	VERB
hsn-1065	64	8	the	the	DET
hsn-1065	64	9	statistical	statistical	ADJ
hsn-1065	64	10	package	package	NOUN
hsn-1065	64	11	for	for	ADP
hsn-1065	64	12	the	the	DET
hsn-1065	64	13	social	social	ADJ
hsn-1065	64	14	sciences	sciences	PROPN
hsn-1065	64	15	(	(	PUNCT
hsn-1065	64	16	spss	spss	PROPN
hsn-1065	64	17	)	)	PUNCT
hsn-1065	64	18	version	version	NOUN
hsn-1065	65	1	[	[	X
hsn-1065	65	2	insert	insert	NOUN
hsn-1065	65	3	version	version	NOUN
hsn-1065	65	4	,	,	PUNCT
hsn-1065	65	5	e.g.	e.g.	ADV
hsn-1065	65	6	,	,	PUNCT
hsn-1065	65	7	25.0	25.0	NUM
hsn-1065	65	8	]	]	PUNCT
hsn-1065	65	9	.	.	PUNCT
hsn-1065	66	1	results	result	NOUN
hsn-1065	66	2	were	be	AUX
hsn-1065	66	3	expressed	express	VERB
hsn-1065	66	4	as	as	ADP
hsn-1065	66	5	mean	mean	NOUN
hsn-1065	66	6	±	±	NUM
hsn-1065	66	7	standard	standard	ADJ
hsn-1065	66	8	deviation	deviation	NOUN
hsn-1065	66	9	(	(	PUNCT
hsn-1065	66	10	sd	sd	NOUN
hsn-1065	66	11	)	)	PUNCT
hsn-1065	66	12	.	.	PUNCT
hsn-1065	67	1	independent	independent	ADJ
hsn-1065	67	2	sample	sample	PROPN
hsn-1065	67	3	t	t	PROPN
hsn-1065	67	4	-	-	PUNCT
hsn-1065	67	5	tests	test	NOUN
hsn-1065	67	6	were	be	AUX
hsn-1065	67	7	used	use	VERB
hsn-1065	67	8	to	to	PART
hsn-1065	67	9	compare	compare	VERB
hsn-1065	67	10	the	the	DET
hsn-1065	67	11	mean	mean	ADJ
hsn-1065	67	12	values	value	NOUN
hsn-1065	67	13	between	between	ADP
hsn-1065	67	14	cad	cad	PROPN
hsn-1065	67	15	patients	patient	NOUN
hsn-1065	67	16	and	and	CCONJ
hsn-1065	67	17	controls	control	NOUN
hsn-1065	67	18	,	,	PUNCT
hsn-1065	67	19	as	as	ADV
hsn-1065	67	20	well	well	ADV
hsn-1065	67	21	as	as	ADP
hsn-1065	67	22	between	between	ADP
hsn-1065	67	23	male	male	ADJ
hsn-1065	67	24	and	and	CCONJ
hsn-1065	67	25	female	female	ADJ
hsn-1065	67	26	subgroups	subgroup	NOUN
hsn-1065	67	27	.	.	PUNCT
hsn-1065	68	1	pearson	pearson	PROPN
hsn-1065	68	2	correlation	correlation	NOUN
hsn-1065	68	3	was	be	AUX
hsn-1065	68	4	used	use	VERB
hsn-1065	68	5	to	to	PART
hsn-1065	68	6	determine	determine	VERB
hsn-1065	68	7	the	the	DET
hsn-1065	68	8	relationship	relationship	NOUN
hsn-1065	68	9	between	between	ADP
hsn-1065	68	10	aptt	aptt	PROPN
hsn-1065	68	11	,	,	PUNCT
hsn-1065	68	12	rbc	rbc	PROPN
hsn-1065	68	13	,	,	PUNCT
hsn-1065	68	14	and	and	CCONJ
hsn-1065	68	15	wbc	wbc	PROPN
hsn-1065	68	16	.	.	PUNCT
hsn-1065	69	1	a	a	DET
hsn-1065	69	2	p	p	NOUN
hsn-1065	69	3	-	-	PUNCT
hsn-1065	69	4	value	value	NOUN
hsn-1065	69	5	<	<	X
hsn-1065	69	6	0.05	0.05	NUM
hsn-1065	69	7	was	be	AUX
hsn-1065	69	8	considered	consider	VERB
hsn-1065	69	9	statistically	statistically	ADV
hsn-1065	69	10	significant	significant	ADJ
hsn-1065	69	11	.	.	PUNCT
hsn-1065	70	1	3.results	3.results	NUM
hsn-1065	70	2	table	table	NOUN
hsn-1065	70	3	1	1	NUM
hsn-1065	70	4	mean	mean	NOUN
hsn-1065	70	5	values	value	NOUN
hsn-1065	70	6	of	of	ADP
hsn-1065	70	7	aptt	aptt	ADJ
hsn-1065	70	8	,	,	PUNCT
hsn-1065	70	9	red	red	ADJ
hsn-1065	70	10	blood	blood	NOUN
hsn-1065	70	11	cell	cell	NOUN
hsn-1065	70	12	and	and	CCONJ
hsn-1065	70	13	white	white	ADJ
hsn-1065	70	14	blood	blood	NOUN
hsn-1065	70	15	cell	cell	NOUN
hsn-1065	70	16	counts	count	NOUN
hsn-1065	70	17	in	in	ADP
hsn-1065	70	18	patients	patient	NOUN
hsn-1065	70	19	with	with	ADP
hsn-1065	70	20	coronary	coronary	ADJ
hsn-1065	70	21	artery	artery	NOUN
hsn-1065	70	22	disease	disease	NOUN
hsn-1065	70	23	and	and	CCONJ
hsn-1065	70	24	healthy	healthy	ADJ
hsn-1065	70	25	subjects	subject	NOUN
hsn-1065	70	26	(	(	PUNCT
hsn-1065	70	27	mean	mean	PROPN
hsn-1065	70	28	±	±	NUM
hsn-1065	70	29	s.d	s.d	PROPN
hsn-1065	70	30	)	)	PUNCT
hsn-1065	70	31	table	table	NOUN
hsn-1065	70	32	1	1	NUM
hsn-1065	70	33	shows	show	VERB
hsn-1065	70	34	the	the	DET
hsn-1065	70	35	mean	mean	ADJ
hsn-1065	70	36	levels	level	NOUN
hsn-1065	70	37	of	of	ADP
hsn-1065	70	38	aptt	aptt	PROPN
hsn-1065	70	39	.	.	PUNCT
hsn-1065	71	1	red	red	ADJ
hsn-1065	71	2	blood	blood	NOUN
hsn-1065	71	3	cell	cell	NOUN
hsn-1065	71	4	and	and	CCONJ
hsn-1065	71	5	white	white	ADJ
hsn-1065	71	6	blood	blood	NOUN
hsn-1065	71	7	cell	cell	NOUN
hsn-1065	71	8	counts	count	NOUN
hsn-1065	71	9	in	in	ADP
hsn-1065	71	10	patients	patient	NOUN
hsn-1065	71	11	with	with	ADP
hsn-1065	71	12	coronary	coronary	ADJ
hsn-1065	71	13	artery	artery	NOUN
hsn-1065	71	14	disease	disease	NOUN
hsn-1065	71	15	and	and	CCONJ
hsn-1065	71	16	healthy	healthy	ADJ
hsn-1065	71	17	subjects	subject	NOUN
hsn-1065	71	18	the	the	DET
hsn-1065	71	19	mean	mean	ADJ
hsn-1065	71	20	values	value	NOUN
hsn-1065	71	21	of	of	ADP
hsn-1065	71	22	aptt	aptt	NOUN
hsn-1065	71	23	(	(	PUNCT
hsn-1065	71	24	41.23±	41.23±	NOUN
hsn-1065	71	25	4.09)secs	4.09)secs	NUM
hsn-1065	71	26	and	and	CCONJ
hsn-1065	71	27	wbc	wbc	PROPN
hsn-1065	71	28	(	(	PUNCT
hsn-1065	71	29	15.23±	15.23±	NUM
hsn-1065	71	30	2.1	2.1	NUM
hsn-1065	71	31	)	)	PUNCT
hsn-1065	71	32	x	x	SYM
hsn-1065	71	33	109	109	NUM
hsn-1065	71	34	/l	/l	PUNCT
hsn-1065	71	35	in	in	ADP
hsn-1065	71	36	patients	patient	NOUN
hsn-1065	71	37	with	with	ADP
hsn-1065	71	38	coronary	coronary	ADJ
hsn-1065	71	39	heart	heart	NOUN
hsn-1065	71	40	disease	disease	NOUN
hsn-1065	71	41	were	be	AUX
hsn-1065	71	42	significantly	significantly	ADV
hsn-1065	71	43	raised	raise	VERB
hsn-1065	71	44	when	when	SCONJ
hsn-1065	71	45	compared	compare	VERB
hsn-1065	71	46	to	to	ADP
hsn-1065	71	47	that	that	PRON
hsn-1065	71	48	of	of	ADP
hsn-1065	71	49	the	the	DET
hsn-1065	71	50	controls	control	NOUN
hsn-1065	71	51	(	(	PUNCT
hsn-1065	71	52	28.30±	28.30±	NUM
hsn-1065	71	53	2.17)secs	2.17)secs	NUM
hsn-1065	71	54	and	and	CCONJ
hsn-1065	71	55	(	(	PUNCT
hsn-1065	71	56	7.00±	7.00±	NOUN
hsn-1065	71	57	1.68	1.68	NUM
hsn-1065	71	58	)	)	PUNCT
hsn-1065	71	59	x	x	SYM
hsn-1065	71	60	109	109	NUM
hsn-1065	71	61	/l	/l	PUNCT
hsn-1065	71	62	respectively	respectively	ADV
hsn-1065	71	63	(	(	PUNCT
hsn-1065	71	64	t=	t=	NOUN
hsn-1065	71	65	20.01	20.01	NUM
hsn-1065	71	66	,	,	PUNCT
hsn-1065	71	67	p=	p=	NOUN
hsn-1065	71	68	0.002	0.002	NUM
hsn-1065	71	69	and	and	CCONJ
hsn-1065	71	70	t=59.58	t=59.58	PROPN
hsn-1065	71	71	,	,	PUNCT
hsn-1065	71	72	p=	p=	X
hsn-1065	71	73	<	<	X
hsn-1065	71	74	0.001	0.001	NUM
hsn-1065	71	75	)	)	PUNCT
hsn-1065	71	76	on	on	ADP
hsn-1065	71	77	the	the	DET
hsn-1065	71	78	other	other	ADJ
hsn-1065	71	79	hand	hand	NOUN
hsn-1065	71	80	,	,	PUNCT
hsn-1065	71	81	the	the	DET
hsn-1065	71	82	mean	mean	ADJ
hsn-1065	71	83	values	value	NOUN
hsn-1065	71	84	of	of	ADP
hsn-1065	71	85	rbc	rbc	PROPN
hsn-1065	71	86	(	(	PUNCT
hsn-1065	71	87	2.07±	2.07±	NUM
hsn-1065	71	88	0.35	0.35	NUM
hsn-1065	71	89	)	)	PUNCT
hsn-1065	71	90	x	x	SYM
hsn-1065	71	91	1012	1012	NUM
hsn-1065	71	92	/l	/l	PUNCT
hsn-1065	71	93	in	in	ADP
hsn-1065	71	94	patients	patient	NOUN
hsn-1065	71	95	with	with	ADP
hsn-1065	71	96	coronary	coronary	ADJ
hsn-1065	71	97	heart	heart	NOUN
hsn-1065	71	98	disease	disease	NOUN
hsn-1065	71	99	were	be	AUX
hsn-1065	71	100	significantly	significantly	ADV
hsn-1065	71	101	reduced	reduce	VERB
hsn-1065	71	102	when	when	SCONJ
hsn-1065	71	103	compared	compare	VERB
hsn-1065	71	104	to	to	ADP
hsn-1065	71	105	that	that	PRON
hsn-1065	71	106	of	of	ADP
hsn-1065	71	107	the	the	DET
hsn-1065	71	108	controls	control	NOUN
hsn-1065	71	109	(	(	PUNCT
hsn-1065	71	110	4.01±	4.01±	NOUN
hsn-1065	71	111	0.27	0.27	NUM
hsn-1065	71	112	)	)	PUNCT
hsn-1065	71	113	x	x	SYM
hsn-1065	71	114	1012	1012	NUM
hsn-1065	71	115	/l(t	/l(t	PUNCT
hsn-1065	71	116	=	=	PUNCT
hsn-1065	71	117	5.66	5.66	NUM
hsn-1065	71	118	,	,	PUNCT
hsn-1065	71	119	p	p	NOUN
hsn-1065	71	120	=	=	X
hsn-1065	71	121	<	<	X
hsn-1065	71	122	0.001	0.001	NUM
hsn-1065	71	123	)	)	PUNCT
hsn-1065	71	124	ijo	ijo	PROPN
hsn-1065	71	125	journals	journal	NOUN
hsn-1065	71	126	volume	volume	NOUN
hsn-1065	71	127	08	08	NUM
hsn-1065	72	1	|	|	ADV
hsn-1065	72	2	issue	issue	VERB
hsn-1065	72	3	04	04	NUM
hsn-1065	73	1	|	|	CCONJ
hsn-1065	73	2	april	april	PROPN
hsn-1065	73	3	2025	2025	NUM
hsn-1065	73	4	|	|	ADV
hsn-1065	73	5	https://ijojournals.com/index.php/hsn/index	https://ijojournals.com/index.php/hsn/index	NOUN
hsn-1065	73	6	4	4	NUM
hsn-1065	73	7	ijo	ijo	PROPN
hsn-1065	73	8	international	international	ADJ
hsn-1065	73	9	journal	journal	PROPN
hsn-1065	73	10	of	of	ADP
hsn-1065	73	11	health	health	PROPN
hsn-1065	73	12	sciences	sciences	PROPN
hsn-1065	73	13	and	and	CCONJ
hsn-1065	73	14	nursing	nursing	NOUN
hsn-1065	73	15	(	(	PUNCT
hsn-1065	73	16	issn	issn	PROPN
hsn-1065	73	17	:	:	PUNCT
hsn-1065	73	18	2814	2814	NUM
hsn-1065	73	19	-	-	SYM
hsn-1065	73	20	2098	2098	NUM
hsn-1065	73	21	)	)	PUNCT
hsn-1065	73	22	chinedu	chinedu	NOUN
hsn-1065	73	23	-	-	PUNCT
hsn-1065	73	24	madu	madu	NOUN
hsn-1065	73	25	jane	jane	NOUN
hsn-1065	73	26	u	u	NOUN
hsn-1065	74	1	1	1	NUM
hsn-1065	74	2	*	*	PUNCT
hsn-1065	74	3	https://ijojournals.com/	https://ijojournals.com/	NOUN
hsn-1065	74	4	volume	volume	NOUN
hsn-1065	74	5	08	08	NUM
hsn-1065	74	6	||	||	PROPN
hsn-1065	74	7	issue	issue	NOUN
hsn-1065	74	8	04	04	NUM
hsn-1065	74	9	||	||	NOUN
hsn-1065	74	10	april	april	PROPN
hsn-1065	74	11	,	,	PUNCT
hsn-1065	74	12	2025	2025	NUM
hsn-1065	74	13	||	||	PUNCT
hsn-1065	75	1	“	"	PUNCT
hsn-1065	75	2	studies	study	NOUN
hsn-1065	75	3	on	on	ADP
hsn-1065	75	4	activated	activate	VERB
hsn-1065	75	5	partial	partial	ADJ
hsn-1065	75	6	thromboplastin	thromboplastin	NOUN
hsn-1065	75	7	time	time	NOUN
hsn-1065	75	8	,	,	PUNCT
hsn-1065	75	9	red	red	ADJ
hsn-1065	75	10	and	and	CCONJ
hsn-1065	75	11	white	white	ADJ
hsn-1065	75	12	blood	blood	NOUN
hsn-1065	75	13	cell	cell	NOUN
hsn-1065	75	14	counts	count	NOUN
hsn-1065	75	15	in	in	ADP
hsn-1065	75	16	coronary	coronary	ADJ
hsn-1065	75	17	artery	artery	NOUN
hsn-1065	75	18	disease	disease	NOUN
hsn-1065	75	19	in	in	ADP
hsn-1065	75	20	owerri	owerri	PROPN
hsn-1065	75	21	,	,	PUNCT
hsn-1065	75	22	nigeria	nigeria	PROPN
hsn-1065	75	23	..	..	PUNCT
hsn-1065	75	24	"	"	PUNCT
hsn-1065	75	25	parameters	parameter	NOUN
hsn-1065	75	26	no	no	DET
hsn-1065	75	27	test	test	NOUN
hsn-1065	75	28	(	(	PUNCT
hsn-1065	75	29	n=30	n=30	NOUN
hsn-1065	75	30	)	)	PUNCT
hsn-1065	75	31	control	control	NOUN
hsn-1065	75	32	(	(	PUNCT
hsn-1065	75	33	n=30	n=30	NOUN
hsn-1065	75	34	)	)	PUNCT
hsn-1065	75	35	t	t	NOUN
hsn-1065	75	36	-	-	PUNCT
hsn-1065	75	37	value	value	NOUN
hsn-1065	75	38	p	p	NOUN
hsn-1065	75	39	value	value	NOUN
hsn-1065	75	40	aptt	aptt	ADJ
hsn-1065	75	41	(	(	PUNCT
hsn-1065	75	42	secs	sec	NOUN
hsn-1065	75	43	)	)	PUNCT
hsn-1065	75	44	30	30	NUM
hsn-1065	75	45	41.23±	41.23±	NUM
hsn-1065	75	46	4.09	4.09	NUM
hsn-1065	75	47	28.3	28.3	NUM
hsn-1065	75	48	±	±	NUM
hsn-1065	75	49	2.17	2.17	NUM
hsn-1065	75	50	20.01	20.01	NUM
hsn-1065	75	51	0.002	0.002	NUM
hsn-1065	75	52	*	*	PUNCT
hsn-1065	75	53	.	.	PUNCT
hsn-1065	76	1	rbc	rbc	PROPN
hsn-1065	76	2	(	(	PUNCT
hsn-1065	76	3	1012	1012	NUM
hsn-1065	76	4	/l	/l	SYM
hsn-1065	76	5	)	)	PUNCT
hsn-1065	76	6	30	30	NUM
hsn-1065	76	7	2.07±0.35	2.07±0.35	NOUN
hsn-1065	76	8	4.09	4.09	NUM
hsn-1065	76	9	±0.27	±0.27	X
hsn-1065	76	10	-5.66	-5.66	NOUN
hsn-1065	76	11	.	.	PUNCT
hsn-1065	76	12	<	<	X
hsn-1065	76	13	0.001	0.001	NUM
hsn-1065	76	14	*	*	NOUN
hsn-1065	76	15	,	,	PUNCT
hsn-1065	76	16	wbc	wbc	INTJ
hsn-1065	76	17	(	(	PUNCT
hsn-1065	76	18	109	109	NUM
hsn-1065	76	19	/	/	SYM
hsn-1065	76	20	l	l	NOUN
hsn-1065	76	21	)	)	PUNCT
hsn-1065	76	22	30	30	NUM
hsn-1065	76	23	15.33±	15.33±	NUM
hsn-1065	76	24	2.15	2.15	NUM
hsn-1065	76	25	7.0	7.0	NUM
hsn-1065	76	26	±	±	NUM
hsn-1065	76	27	1.68	1.68	NUM
hsn-1065	76	28	59.58	59.58	NUM
hsn-1065	76	29	0.001	0.001	NUM
hsn-1065	76	30	*	*	NOUN
hsn-1065	76	31	key	key	NOUN
hsn-1065	76	32	:	:	PUNCT
hsn-1065	76	33	s.dstandard	s.dstandard	ADJ
hsn-1065	76	34	deviation	deviation	NOUN
hsn-1065	76	35	*	*	PUNCT
hsn-1065	76	36	significant	significant	ADJ
hsn-1065	76	37	p	p	NOUN
hsn-1065	76	38	value	value	NOUN
hsn-1065	76	39	apttactivated	apttactivate	VERB
hsn-1065	76	40	partial	partial	ADJ
hsn-1065	76	41	thromboplastin	thromboplastin	NOUN
hsn-1065	76	42	time	time	NOUN
hsn-1065	76	43	rbcred	rbcre	VERB
hsn-1065	76	44	blood	blood	NOUN
hsn-1065	76	45	cell	cell	NOUN
hsn-1065	76	46	wbcwhite	wbcwhite	ADJ
hsn-1065	76	47	blood	blood	NOUN
hsn-1065	76	48	cell	cell	NOUN
hsn-1065	76	49	table	table	NOUN
hsn-1065	76	50	2	2	NUM
hsn-1065	76	51	:	:	PUNCT
hsn-1065	76	52	comparison	comparison	NOUN
hsn-1065	76	53	of	of	ADP
hsn-1065	76	54	levels	level	NOUN
hsn-1065	76	55	of	of	ADP
hsn-1065	76	56	aptt	aptt	ADJ
hsn-1065	76	57	,	,	PUNCT
hsn-1065	76	58	red	red	ADJ
hsn-1065	76	59	blood	blood	NOUN
hsn-1065	76	60	cell	cell	NOUN
hsn-1065	76	61	and	and	CCONJ
hsn-1065	76	62	white	white	ADJ
hsn-1065	76	63	blood	blood	NOUN
hsn-1065	76	64	cell	cell	NOUN
hsn-1065	76	65	counts	count	NOUN
hsn-1065	76	66	in	in	ADP
hsn-1065	76	67	male	male	ADJ
hsn-1065	76	68	and	and	CCONJ
hsn-1065	76	69	female	female	ADJ
hsn-1065	76	70	patients	patient	NOUN
hsn-1065	76	71	with	with	ADP
hsn-1065	76	72	coronary	coronary	ADJ
hsn-1065	76	73	artery	artery	NOUN
hsn-1065	76	74	disease	disease	NOUN
hsn-1065	76	75	table	table	NOUN
hsn-1065	76	76	.2	.2	NUM
hsn-1065	76	77	shows	show	VERB
hsn-1065	76	78	the	the	DET
hsn-1065	76	79	mean	mean	ADJ
hsn-1065	76	80	values	value	NOUN
hsn-1065	76	81	of	of	ADP
hsn-1065	76	82	aptt	aptt	ADJ
hsn-1065	76	83	,	,	PUNCT
hsn-1065	76	84	red	red	ADJ
hsn-1065	76	85	blood	blood	NOUN
hsn-1065	76	86	cell	cell	NOUN
hsn-1065	76	87	and	and	CCONJ
hsn-1065	76	88	white	white	ADJ
hsn-1065	76	89	blood	blood	NOUN
hsn-1065	76	90	cell	cell	NOUN
hsn-1065	76	91	counts	count	NOUN
hsn-1065	76	92	in	in	ADP
hsn-1065	76	93	male	male	ADJ
hsn-1065	76	94	and	and	CCONJ
hsn-1065	76	95	female	female	ADJ
hsn-1065	76	96	patients	patient	NOUN
hsn-1065	76	97	with	with	ADP
hsn-1065	76	98	coronary	coronary	ADJ
hsn-1065	76	99	artery	artery	NOUN
hsn-1065	76	100	disease	disease	NOUN
hsn-1065	76	101	.	.	PUNCT
hsn-1065	77	1	the	the	DET
hsn-1065	77	2	mean	mean	ADJ
hsn-1065	77	3	values	value	NOUN
hsn-1065	77	4	of	of	ADP
hsn-1065	77	5	aptt	aptt	PROPN
hsn-1065	77	6	(	(	PUNCT
hsn-1065	77	7	65.30±	65.30±	NUM
hsn-1065	77	8	14.48)secs	14.48)sec	NOUN
hsn-1065	77	9	in	in	ADP
hsn-1065	77	10	male	male	ADJ
hsn-1065	77	11	patients	patient	NOUN
hsn-1065	77	12	with	with	ADP
hsn-1065	77	13	coronary	coronary	ADJ
hsn-1065	77	14	heart	heart	NOUN
hsn-1065	77	15	disease	disease	NOUN
hsn-1065	77	16	was	be	AUX
hsn-1065	77	17	significantly	significantly	ADV
hsn-1065	77	18	increased	increase	VERB
hsn-1065	77	19	when	when	SCONJ
hsn-1065	77	20	compared	compare	VERB
hsn-1065	77	21	to	to	ADP
hsn-1065	77	22	female	female	ADJ
hsn-1065	77	23	patients	patient	NOUN
hsn-1065	77	24	with	with	ADP
hsn-1065	77	25	coronary	coronary	ADJ
hsn-1065	77	26	heart	heart	NOUN
hsn-1065	77	27	disease	disease	NOUN
hsn-1065	77	28	(	(	PUNCT
hsn-1065	77	29	48.60±	48.60±	NUM
hsn-1065	77	30	8.95)secs	8.95)secs	NUM
hsn-1065	77	31	(	(	PUNCT
hsn-1065	77	32	t=	t=	NOUN
hsn-1065	77	33	3.880	3.880	NUM
hsn-1065	77	34	,	,	PUNCT
hsn-1065	77	35	p=	p=	NOUN
hsn-1065	77	36	0.035	0.035	NUM
hsn-1065	77	37	)	)	PUNCT
hsn-1065	77	38	the	the	DET
hsn-1065	77	39	mean	mean	ADJ
hsn-1065	77	40	values	value	NOUN
hsn-1065	77	41	of	of	ADP
hsn-1065	77	42	rbc	rbc	PROPN
hsn-1065	77	43	(	(	PUNCT
hsn-1065	77	44	2.36±	2.36±	NOUN
hsn-1065	77	45	0.32	0.32	NUM
hsn-1065	77	46	)	)	PUNCT
hsn-1065	77	47	x	x	SYM
hsn-1065	77	48	1012	1012	NUM
hsn-1065	77	49	/l	/l	PUNCT
hsn-1065	77	50	in	in	ADP
hsn-1065	77	51	male	male	ADJ
hsn-1065	77	52	patients	patient	NOUN
hsn-1065	77	53	with	with	ADP
hsn-1065	77	54	coronary	coronary	ADJ
hsn-1065	77	55	heart	heart	NOUN
hsn-1065	77	56	disease	disease	NOUN
hsn-1065	77	57	was	be	AUX
hsn-1065	77	58	insignificantly	insignificantly	ADV
hsn-1065	77	59	increased	increase	VERB
hsn-1065	77	60	when	when	SCONJ
hsn-1065	77	61	compared	compare	VERB
hsn-1065	77	62	to	to	ADP
hsn-1065	77	63	female	female	ADJ
hsn-1065	77	64	patients	patient	NOUN
hsn-1065	77	65	with	with	ADP
hsn-1065	77	66	coronary	coronary	ADJ
hsn-1065	77	67	heart	heart	NOUN
hsn-1065	77	68	disease	disease	NOUN
hsn-1065	77	69	(	(	PUNCT
hsn-1065	77	70	1.92±	1.92±	NOUN
hsn-1065	77	71	0.22	0.22	NUM
hsn-1065	77	72	)	)	PUNCT
hsn-1065	77	73	x	x	SYM
hsn-1065	77	74	1012	1012	NUM
hsn-1065	77	75	/l	/l	PUNCT
hsn-1065	78	1	(	(	PUNCT
hsn-1065	78	2	t=	t=	NOUN
hsn-1065	78	3	1.827	1.827	NUM
hsn-1065	78	4	,	,	PUNCT
hsn-1065	78	5	p=	p=	NOUN
hsn-1065	78	6	0.076	0.076	NUM
hsn-1065	78	7	)	)	PUNCT
hsn-1065	78	8	the	the	DET
hsn-1065	78	9	mean	mean	ADJ
hsn-1065	78	10	values	value	NOUN
hsn-1065	78	11	of	of	ADP
hsn-1065	78	12	wbc	wbc	PROPN
hsn-1065	78	13	(	(	PUNCT
hsn-1065	78	14	13.95±	13.95±	NUM
hsn-1065	78	15	2.20	2.20	NUM
hsn-1065	78	16	)	)	PUNCT
hsn-1065	78	17	x	x	SYM
hsn-1065	78	18	109	109	NUM
hsn-1065	78	19	/l	/l	PUNCT
hsn-1065	78	20	in	in	ADP
hsn-1065	78	21	male	male	ADJ
hsn-1065	78	22	patients	patient	NOUN
hsn-1065	78	23	with	with	ADP
hsn-1065	78	24	coronary	coronary	ADJ
hsn-1065	78	25	heart	heart	NOUN
hsn-1065	78	26	disease	disease	NOUN
hsn-1065	78	27	was	be	AUX
hsn-1065	78	28	insignificantly	insignificantly	ADV
hsn-1065	78	29	reduced	reduce	VERB
hsn-1065	78	30	when	when	SCONJ
hsn-1065	78	31	compared	compare	VERB
hsn-1065	78	32	to	to	ADP
hsn-1065	78	33	female	female	ADJ
hsn-1065	78	34	patients	patient	NOUN
hsn-1065	78	35	with	with	ADP
hsn-1065	78	36	coronary	coronary	ADJ
hsn-1065	78	37	heart	heart	NOUN
hsn-1065	78	38	disease	disease	NOUN
hsn-1065	78	39	(	(	PUNCT
hsn-1065	78	40	16.60±	16.60±	NUM
hsn-1065	78	41	5.68	5.68	NUM
hsn-1065	78	42	)	)	PUNCT
hsn-1065	78	43	x	x	SYM
hsn-1065	78	44	1012	1012	NUM
hsn-1065	78	45	/l	/l	PUNCT
hsn-1065	78	46	(	(	PUNCT
hsn-1065	78	47	t=	t=	NOUN
hsn-1065	78	48	-1.421	-1.421	NOUN
hsn-1065	78	49	,	,	PUNCT
hsn-1065	78	50	p=	p=	PROPN
hsn-1065	78	51	0.167	0.167	NUM
hsn-1065	78	52	)	)	PUNCT
hsn-1065	78	53	ijo	ijo	PROPN
hsn-1065	78	54	journals	journal	NOUN
hsn-1065	78	55	volume	volume	NOUN
hsn-1065	78	56	08	08	NUM
hsn-1065	79	1	|	|	ADV
hsn-1065	79	2	issue	issue	VERB
hsn-1065	79	3	04	04	NUM
hsn-1065	80	1	|	|	CCONJ
hsn-1065	80	2	april	april	PROPN
hsn-1065	80	3	2025	2025	NUM
hsn-1065	81	1	|	|	ADV
hsn-1065	81	2	https://ijojournals.com/index.php/hsn/index	https://ijojournals.com/index.php/hsn/index	NOUN
hsn-1065	81	3	5	5	NUM
hsn-1065	81	4	ijo	ijo	PROPN
hsn-1065	81	5	international	international	PROPN
hsn-1065	81	6	journal	journal	PROPN
hsn-1065	81	7	of	of	ADP
hsn-1065	81	8	health	health	PROPN
hsn-1065	81	9	sciences	sciences	PROPN
hsn-1065	81	10	and	and	CCONJ
hsn-1065	81	11	nursing	nursing	NOUN
hsn-1065	81	12	(	(	PUNCT
hsn-1065	81	13	issn	issn	PROPN
hsn-1065	81	14	:	:	PUNCT
hsn-1065	81	15	2814	2814	NUM
hsn-1065	81	16	-	-	SYM
hsn-1065	81	17	2098	2098	NUM
hsn-1065	81	18	)	)	PUNCT
hsn-1065	81	19	chinedu	chinedu	NOUN
hsn-1065	81	20	-	-	PUNCT
hsn-1065	81	21	madu	madu	NOUN
hsn-1065	81	22	jane	jane	NOUN
hsn-1065	81	23	u	u	NOUN
hsn-1065	81	24	1	1	NUM
hsn-1065	81	25	*	*	PUNCT
hsn-1065	81	26	https://ijojournals.com/	https://ijojournals.com/	NOUN
hsn-1065	81	27	volume	volume	NOUN
hsn-1065	81	28	08	08	NUM
hsn-1065	81	29	||	||	PROPN
hsn-1065	81	30	issue	issue	NOUN
hsn-1065	81	31	04	04	NUM
hsn-1065	81	32	||	||	NOUN
hsn-1065	81	33	april	april	PROPN
hsn-1065	81	34	,	,	PUNCT
hsn-1065	81	35	2025	2025	NUM
hsn-1065	81	36	||	||	PUNCT
hsn-1065	82	1	“	"	PUNCT
hsn-1065	82	2	studies	study	NOUN
hsn-1065	82	3	on	on	ADP
hsn-1065	82	4	activated	activate	VERB
hsn-1065	82	5	partial	partial	ADJ
hsn-1065	82	6	thromboplastin	thromboplastin	NOUN
hsn-1065	82	7	time	time	NOUN
hsn-1065	82	8	,	,	PUNCT
hsn-1065	82	9	red	red	ADJ
hsn-1065	82	10	and	and	CCONJ
hsn-1065	82	11	white	white	ADJ
hsn-1065	82	12	blood	blood	NOUN
hsn-1065	82	13	cell	cell	NOUN
hsn-1065	82	14	counts	count	NOUN
hsn-1065	82	15	in	in	ADP
hsn-1065	82	16	coronary	coronary	ADJ
hsn-1065	82	17	artery	artery	NOUN
hsn-1065	82	18	disease	disease	NOUN
hsn-1065	82	19	in	in	ADP
hsn-1065	82	20	owerri	owerri	PROPN
hsn-1065	82	21	,	,	PUNCT
hsn-1065	82	22	nigeria	nigeria	PROPN
hsn-1065	82	23	..	..	PUNCT
hsn-1065	82	24	"	"	PUNCT
hsn-1065	82	25	parameters	parameter	NOUN
hsn-1065	82	26	no	no	DET
hsn-1065	82	27	male	male	NOUN
hsn-1065	82	28	(	(	PUNCT
hsn-1065	82	29	n=19	n=19	ADJ
hsn-1065	82	30	)	)	PUNCT
hsn-1065	82	31	female	female	ADJ
hsn-1065	82	32	(	(	PUNCT
hsn-1065	82	33	n=11	n=11	NOUN
hsn-1065	82	34	)	)	PUNCT
hsn-1065	82	35	t	t	NOUN
hsn-1065	82	36	-	-	PUNCT
hsn-1065	82	37	value	value	NOUN
hsn-1065	82	38	p	p	NOUN
hsn-1065	82	39	value	value	NOUN
hsn-1065	82	40	aptt	aptt	ADJ
hsn-1065	82	41	(	(	PUNCT
hsn-1065	82	42	secs	sec	NOUN
hsn-1065	82	43	)	)	PUNCT
hsn-1065	82	44	30	30	NUM
hsn-1065	82	45	65.3±	65.3±	NOUN
hsn-1065	82	46	14.48	14.48	NUM
hsn-1065	82	47	48.6±	48.6±	NOUN
hsn-1065	82	48	8.95	8.95	NUM
hsn-1065	82	49	3.88	3.88	NUM
hsn-1065	82	50	0.035	0.035	NUM
hsn-1065	82	51	*	*	PUNCT
hsn-1065	82	52	.	.	PUNCT
hsn-1065	83	1	rbc	rbc	PROPN
hsn-1065	83	2	(	(	PUNCT
hsn-1065	83	3	1012	1012	NUM
hsn-1065	83	4	/l	/l	SYM
hsn-1065	83	5	)	)	PUNCT
hsn-1065	83	6	30	30	NUM
hsn-1065	84	1	2.36±0.32	2.36±0.32	NUM
hsn-1065	84	2	1.92±0.22	1.92±0.22	NUM
hsn-1065	84	3	1.83	1.83	NUM
hsn-1065	84	4	0.076	0.076	NUM
hsn-1065	84	5	wbc	wbc	NOUN
hsn-1065	84	6	(	(	PUNCT
hsn-1065	84	7	109	109	NUM
hsn-1065	84	8	/	/	SYM
hsn-1065	84	9	l	l	NOUN
hsn-1065	84	10	)	)	PUNCT
hsn-1065	84	11	30	30	NUM
hsn-1065	84	12	13.95±	13.95±	NUM
hsn-1065	84	13	2.2	2.2	NUM
hsn-1065	84	14	16.6±	16.6±	NOUN
hsn-1065	84	15	5.68	5.68	NUM
hsn-1065	84	16	−1.421	−1.421	PROPN
hsn-1065	84	17	0.167	0.167	NUM
hsn-1065	84	18	key	key	NOUN
hsn-1065	84	19	:	:	PUNCT
hsn-1065	84	20	s.dstandard	s.dstandard	ADJ
hsn-1065	84	21	deviation	deviation	NOUN
hsn-1065	84	22	*	*	PUNCT
hsn-1065	84	23	significant	significant	ADJ
hsn-1065	84	24	p	p	NOUN
hsn-1065	84	25	value	value	NOUN
hsn-1065	84	26	apttactivated	apttactivate	VERB
hsn-1065	84	27	partial	partial	ADJ
hsn-1065	84	28	thromboplastin	thromboplastin	NOUN
hsn-1065	84	29	time	time	NOUN
hsn-1065	84	30	rbcred	rbcre	VERB
hsn-1065	84	31	blood	blood	NOUN
hsn-1065	84	32	cell	cell	NOUN
hsn-1065	84	33	wbcwhite	wbcwhite	ADJ
hsn-1065	84	34	blood	blood	NOUN
hsn-1065	84	35	cell	cell	NOUN
hsn-1065	84	36	table	table	NOUN
hsn-1065	84	37	3	3	NUM
hsn-1065	84	38	:	:	PUNCT
hsn-1065	84	39	correlation	correlation	NOUN
hsn-1065	84	40	of	of	ADP
hsn-1065	84	41	aptt	aptt	NOUN
hsn-1065	84	42	with	with	ADP
hsn-1065	84	43	red	red	ADJ
hsn-1065	84	44	blood	blood	NOUN
hsn-1065	84	45	cell	cell	NOUN
hsn-1065	84	46	and	and	CCONJ
hsn-1065	84	47	white	white	ADJ
hsn-1065	84	48	blood	blood	NOUN
hsn-1065	84	49	cell	cell	NOUN
hsn-1065	84	50	counts	count	NOUN
hsn-1065	84	51	in	in	ADP
hsn-1065	84	52	patients	patient	NOUN
hsn-1065	84	53	with	with	ADP
hsn-1065	84	54	coronary	coronary	ADJ
hsn-1065	84	55	artery	artery	NOUN
hsn-1065	84	56	disease	disease	NOUN
hsn-1065	84	57	table	table	NOUN
hsn-1065	84	58	3	3	NUM
hsn-1065	84	59	showed	show	VERB
hsn-1065	84	60	the	the	DET
hsn-1065	84	61	correlation	correlation	NOUN
hsn-1065	84	62	ofaptt	ofaptt	NOUN
hsn-1065	84	63	with	with	ADP
hsn-1065	84	64	red	red	ADJ
hsn-1065	84	65	blood	blood	NOUN
hsn-1065	84	66	cell	cell	NOUN
hsn-1065	84	67	and	and	CCONJ
hsn-1065	84	68	white	white	ADJ
hsn-1065	84	69	blood	blood	NOUN
hsn-1065	84	70	cell	cell	NOUN
hsn-1065	84	71	counts	count	NOUN
hsn-1065	84	72	in	in	ADP
hsn-1065	84	73	patients	patient	NOUN
hsn-1065	84	74	with	with	ADP
hsn-1065	84	75	coronary	coronary	ADJ
hsn-1065	84	76	artery	artery	NOUN
hsn-1065	84	77	disease	disease	NOUN
hsn-1065	84	78	there	there	PRON
hsn-1065	84	79	was	be	VERB
hsn-1065	84	80	a	a	DET
hsn-1065	84	81	nonsignificant	nonsignificant	ADJ
hsn-1065	84	82	negative	negative	ADJ
hsn-1065	84	83	correlation	correlation	NOUN
hsn-1065	84	84	of	of	ADP
hsn-1065	84	85	aptt	aptt	NOUN
hsn-1065	84	86	with	with	ADP
hsn-1065	84	87	red	red	ADJ
hsn-1065	84	88	blood	blood	NOUN
hsn-1065	84	89	cell	cell	NOUN
hsn-1065	84	90	(	(	PUNCT
hsn-1065	84	91	r=	r=	ADJ
hsn-1065	84	92	-0.025	-0.025	PUNCT
hsn-1065	84	93	,	,	PUNCT
hsn-1065	84	94	p=0.897	p=0.897	PUNCT
hsn-1065	84	95	)	)	PUNCT
hsn-1065	84	96	among	among	ADP
hsn-1065	84	97	patients	patient	NOUN
hsn-1065	84	98	with	with	ADP
hsn-1065	84	99	coronary	coronary	ADJ
hsn-1065	84	100	artery	artery	NOUN
hsn-1065	84	101	disease	disease	NOUN
hsn-1065	84	102	,	,	PUNCT
hsn-1065	84	103	and	and	CCONJ
hsn-1065	84	104	a	a	DET
hsn-1065	84	105	nonsignificant	nonsignificant	ADJ
hsn-1065	84	106	negative	negative	ADJ
hsn-1065	84	107	correlation	correlation	NOUN
hsn-1065	84	108	with	with	ADP
hsn-1065	84	109	white	white	ADJ
hsn-1065	84	110	blood	blood	NOUN
hsn-1065	84	111	cell	cell	NOUN
hsn-1065	84	112	(	(	PUNCT
hsn-1065	84	113	r=	r=	PROPN
hsn-1065	84	114	-0.038	-0.038	NOUN
hsn-1065	84	115	,	,	PUNCT
hsn-1065	84	116	p=0.843	p=0.843	NOUN
hsn-1065	84	117	)	)	PUNCT
hsn-1065	84	118	among	among	ADP
hsn-1065	84	119	patients	patient	NOUN
hsn-1065	84	120	with	with	ADP
hsn-1065	84	121	coronary	coronary	ADJ
hsn-1065	84	122	artery	artery	NOUN
hsn-1065	84	123	disease	disease	NOUN
hsn-1065	84	124	ijo	ijo	PROPN
hsn-1065	84	125	journals	journal	NOUN
hsn-1065	84	126	volume	volume	NOUN
hsn-1065	84	127	08	08	NUM
hsn-1065	84	128	|	|	ADV
hsn-1065	84	129	issue	issue	VERB
hsn-1065	84	130	04	04	NUM
hsn-1065	85	1	|	|	CCONJ
hsn-1065	85	2	april	april	PROPN
hsn-1065	85	3	2025	2025	NUM
hsn-1065	86	1	|	|	ADV
hsn-1065	86	2	https://ijojournals.com/index.php/hsn/index	https://ijojournals.com/index.php/hsn/index	NOUN
hsn-1065	86	3	6	6	NUM
hsn-1065	86	4	ijo	ijo	PROPN
hsn-1065	86	5	international	international	PROPN
hsn-1065	86	6	journal	journal	PROPN
hsn-1065	86	7	of	of	ADP
hsn-1065	86	8	health	health	PROPN
hsn-1065	86	9	sciences	sciences	PROPN
hsn-1065	86	10	and	and	CCONJ
hsn-1065	86	11	nursing	nursing	NOUN
hsn-1065	86	12	(	(	PUNCT
hsn-1065	86	13	issn	issn	PROPN
hsn-1065	86	14	:	:	PUNCT
hsn-1065	86	15	2814	2814	NUM
hsn-1065	86	16	-	-	SYM
hsn-1065	86	17	2098	2098	NUM
hsn-1065	86	18	)	)	PUNCT
hsn-1065	86	19	chinedu	chinedu	NOUN
hsn-1065	86	20	-	-	PUNCT
hsn-1065	86	21	madu	madu	NOUN
hsn-1065	86	22	jane	jane	NOUN
hsn-1065	86	23	u	u	NOUN
hsn-1065	86	24	1	1	NUM
hsn-1065	86	25	*	*	PUNCT
hsn-1065	86	26	https://ijojournals.com/	https://ijojournals.com/	NOUN
hsn-1065	86	27	volume	volume	NOUN
hsn-1065	86	28	08	08	NUM
hsn-1065	86	29	||	||	PROPN
hsn-1065	86	30	issue	issue	NOUN
hsn-1065	86	31	04	04	NUM
hsn-1065	86	32	||	||	NOUN
hsn-1065	86	33	april	april	PROPN
hsn-1065	86	34	,	,	PUNCT
hsn-1065	86	35	2025	2025	NUM
hsn-1065	86	36	||	||	PUNCT
hsn-1065	87	1	“	"	PUNCT
hsn-1065	87	2	studies	study	NOUN
hsn-1065	87	3	on	on	ADP
hsn-1065	87	4	activated	activate	VERB
hsn-1065	87	5	partial	partial	ADJ
hsn-1065	87	6	thromboplastin	thromboplastin	NOUN
hsn-1065	87	7	time	time	NOUN
hsn-1065	87	8	,	,	PUNCT
hsn-1065	87	9	red	red	ADJ
hsn-1065	87	10	and	and	CCONJ
hsn-1065	87	11	white	white	ADJ
hsn-1065	87	12	blood	blood	NOUN
hsn-1065	87	13	cell	cell	NOUN
hsn-1065	87	14	counts	count	NOUN
hsn-1065	87	15	in	in	ADP
hsn-1065	87	16	coronary	coronary	ADJ
hsn-1065	87	17	artery	artery	NOUN
hsn-1065	87	18	disease	disease	NOUN
hsn-1065	87	19	in	in	ADP
hsn-1065	87	20	owerri	owerri	PROPN
hsn-1065	87	21	,	,	PUNCT
hsn-1065	87	22	nigeria	nigeria	PROPN
hsn-1065	87	23	..	..	PUNCT
hsn-1065	87	24	"	"	PUNCT
hsn-1065	87	25	parameters	parameter	NOUN
hsn-1065	87	26	n	n	ADP
hsn-1065	87	27	r	r	NOUN
hsn-1065	87	28	p	p	ADJ
hsn-1065	87	29	-	-	PUNCT
hsn-1065	87	30	value	value	NOUN
hsn-1065	87	31	red	red	ADJ
hsn-1065	87	32	blood	blood	NOUN
hsn-1065	87	33	cell	cell	NOUN
hsn-1065	87	34	30	30	NUM
hsn-1065	87	35	-0.025	-0.025	NOUN
hsn-1065	87	36	0.897	0.897	NUM
hsn-1065	87	37	white	white	ADJ
hsn-1065	87	38	blood	blood	NOUN
hsn-1065	87	39	cells	cell	NOUN
hsn-1065	87	40	30	30	NUM
hsn-1065	87	41	-0.038	-0.038	NOUN
hsn-1065	87	42	0.843	0.843	NUM
hsn-1065	87	43	4	4	NUM
hsn-1065	87	44	.	.	PUNCT
hsn-1065	87	45	discussion	discussion	NOUN
hsn-1065	87	46	this	this	DET
hsn-1065	87	47	study	study	NOUN
hsn-1065	87	48	observed	observe	VERB
hsn-1065	87	49	that	that	SCONJ
hsn-1065	87	50	aptt	aptt	PROPN
hsn-1065	87	51	and	and	CCONJ
hsn-1065	87	52	wbc	wbc	ADJ
hsn-1065	87	53	counts	count	NOUN
hsn-1065	87	54	were	be	AUX
hsn-1065	87	55	significantly	significantly	ADV
hsn-1065	87	56	elevated	elevate	VERB
hsn-1065	87	57	in	in	ADP
hsn-1065	87	58	cad	cad	PROPN
hsn-1065	87	59	patients	patient	NOUN
hsn-1065	87	60	when	when	SCONJ
hsn-1065	87	61	compared	compare	VERB
hsn-1065	87	62	to	to	ADP
hsn-1065	87	63	controls	control	NOUN
hsn-1065	87	64	,	,	PUNCT
hsn-1065	87	65	while	while	SCONJ
hsn-1065	87	66	rbc	rbc	PROPN
hsn-1065	87	67	counts	count	NOUN
hsn-1065	87	68	were	be	AUX
hsn-1065	87	69	significantly	significantly	ADV
hsn-1065	87	70	reduced	reduce	VERB
hsn-1065	87	71	.	.	PUNCT
hsn-1065	88	1	these	these	DET
hsn-1065	88	2	findings	finding	NOUN
hsn-1065	88	3	suggest	suggest	VERB
hsn-1065	88	4	a	a	DET
hsn-1065	88	5	concurrent	concurrent	ADJ
hsn-1065	88	6	state	state	NOUN
hsn-1065	88	7	of	of	ADP
hsn-1065	88	8	inflammation	inflammation	NOUN
hsn-1065	88	9	and	and	CCONJ
hsn-1065	88	10	potential	potential	ADJ
hsn-1065	88	11	coagulopathy	coagulopathy	ADJ
hsn-1065	88	12	in	in	ADP
hsn-1065	88	13	cad	cad	PROPN
hsn-1065	88	14	,	,	PUNCT
hsn-1065	88	15	consistent	consistent	ADJ
hsn-1065	88	16	with	with	ADP
hsn-1065	88	17	prior	prior	ADJ
hsn-1065	88	18	literature	literature	NOUN
hsn-1065	88	19	[	[	X
hsn-1065	88	20	3,4	3,4	NUM
hsn-1065	88	21	]	]	PUNCT
hsn-1065	88	22	.	.	PUNCT
hsn-1065	89	1	elevated	elevate	VERB
hsn-1065	89	2	aptt	aptt	ADV
hsn-1065	89	3	in	in	ADP
hsn-1065	89	4	cad	cad	PROPN
hsn-1065	89	5	patients	patient	NOUN
hsn-1065	89	6	may	may	AUX
hsn-1065	89	7	reflect	reflect	VERB
hsn-1065	89	8	an	an	DET
hsn-1065	89	9	adaptive	adaptive	ADJ
hsn-1065	89	10	response	response	NOUN
hsn-1065	89	11	to	to	ADP
hsn-1065	89	12	chronic	chronic	VERB
hsn-1065	89	13	endothelial	endothelial	ADJ
hsn-1065	89	14	damage	damage	NOUN
hsn-1065	89	15	or	or	CCONJ
hsn-1065	89	16	a	a	DET
hsn-1065	89	17	prothrombotic	prothrombotic	ADJ
hsn-1065	89	18	state	state	NOUN
hsn-1065	89	19	that	that	PRON
hsn-1065	89	20	is	be	AUX
hsn-1065	89	21	being	be	AUX
hsn-1065	89	22	compensated	compensate	VERB
hsn-1065	89	23	for	for	ADP
hsn-1065	89	24	by	by	ADP
hsn-1065	89	25	anticoagulant	anticoagulant	ADJ
hsn-1065	89	26	factors	factor	NOUN
hsn-1065	89	27	[	[	X
hsn-1065	89	28	7	7	NUM
hsn-1065	89	29	]	]	PUNCT
hsn-1065	89	30	.	.	PUNCT
hsn-1065	90	1	similar	similar	ADJ
hsn-1065	90	2	findings	finding	NOUN
hsn-1065	90	3	were	be	AUX
hsn-1065	90	4	reported	report	VERB
hsn-1065	90	5	by	by	ADP
hsn-1065	90	6	anvari	anvari	PROPN
hsn-1065	90	7	et	et	PROPN
hsn-1065	90	8	al	al	PROPN
hsn-1065	90	9	.	.	PROPN
hsn-1065	90	10	,	,	PUNCT
hsn-1065	90	11	who	who	PRON
hsn-1065	90	12	observed	observe	VERB
hsn-1065	90	13	a	a	DET
hsn-1065	90	14	prolonged	prolonged	ADJ
hsn-1065	90	15	aptt	aptt	NOUN
hsn-1065	90	16	in	in	ADP
hsn-1065	90	17	cad	cad	PROPN
hsn-1065	90	18	patients	patient	NOUN
hsn-1065	90	19	and	and	CCONJ
hsn-1065	90	20	linked	link	VERB
hsn-1065	90	21	it	it	PRON
hsn-1065	90	22	to	to	PART
hsn-1065	90	23	altered	alter	VERB
hsn-1065	90	24	coagulation	coagulation	NOUN
hsn-1065	90	25	dynamics	dynamic	NOUN
hsn-1065	90	26	and	and	CCONJ
hsn-1065	90	27	increased	increase	VERB
hsn-1065	90	28	cardiovascular	cardiovascular	ADJ
hsn-1065	90	29	risk	risk	NOUN
hsn-1065	90	30	[	[	X
hsn-1065	90	31	3	3	NUM
hsn-1065	90	32	]	]	PUNCT
hsn-1065	90	33	.	.	PUNCT
hsn-1065	91	1	furthermore	furthermore	ADV
hsn-1065	91	2	,	,	PUNCT
hsn-1065	91	3	the	the	DET
hsn-1065	91	4	significantly	significantly	ADV
hsn-1065	91	5	higher	high	ADJ
hsn-1065	91	6	aptt	aptt	PROPN
hsn-1065	91	7	observed	observe	VERB
hsn-1065	91	8	in	in	ADP
hsn-1065	91	9	male	male	ADJ
hsn-1065	91	10	patients	patient	NOUN
hsn-1065	91	11	compared	compare	VERB
hsn-1065	91	12	to	to	ADP
hsn-1065	91	13	females	female	NOUN
hsn-1065	91	14	aligns	align	VERB
hsn-1065	91	15	with	with	ADP
hsn-1065	91	16	studies	study	NOUN
hsn-1065	91	17	that	that	PRON
hsn-1065	91	18	suggest	suggest	VERB
hsn-1065	91	19	gender	gender	NOUN
hsn-1065	91	20	-	-	PUNCT
hsn-1065	91	21	based	base	VERB
hsn-1065	91	22	physiological	physiological	ADJ
hsn-1065	91	23	differences	difference	NOUN
hsn-1065	91	24	in	in	ADP
hsn-1065	91	25	coagulation	coagulation	NOUN
hsn-1065	91	26	response	response	NOUN
hsn-1065	91	27	and	and	CCONJ
hsn-1065	91	28	factor	factor	NOUN
hsn-1065	91	29	levels	level	NOUN
hsn-1065	91	30	[	[	X
hsn-1065	91	31	6,8	6,8	NUM
hsn-1065	91	32	]	]	PUNCT
hsn-1065	91	33	.	.	PUNCT
hsn-1065	92	1	the	the	DET
hsn-1065	92	2	elevated	elevated	ADJ
hsn-1065	92	3	wbc	wbc	NOUN
hsn-1065	92	4	count	count	NOUN
hsn-1065	92	5	seen	see	VERB
hsn-1065	92	6	in	in	ADP
hsn-1065	92	7	cad	cad	PROPN
hsn-1065	92	8	patients	patient	NOUN
hsn-1065	92	9	corroborates	corroborate	VERB
hsn-1065	92	10	with	with	ADP
hsn-1065	92	11	earlier	early	ADJ
hsn-1065	92	12	reports	report	NOUN
hsn-1065	92	13	that	that	SCONJ
hsn-1065	92	14	leukocytosis	leukocytosis	NOUN
hsn-1065	92	15	serves	serve	VERB
hsn-1065	92	16	as	as	ADP
hsn-1065	92	17	a	a	DET
hsn-1065	92	18	biomarker	biomarker	NOUN
hsn-1065	92	19	for	for	ADP
hsn-1065	92	20	inflammation	inflammation	NOUN
hsn-1065	92	21	and	and	CCONJ
hsn-1065	92	22	is	be	AUX
hsn-1065	92	23	associated	associate	VERB
hsn-1065	92	24	with	with	ADP
hsn-1065	92	25	the	the	DET
hsn-1065	92	26	development	development	NOUN
hsn-1065	92	27	and	and	CCONJ
hsn-1065	92	28	progression	progression	NOUN
hsn-1065	92	29	of	of	ADP
hsn-1065	92	30	atherosclerosis	atherosclerosis	NOUN
hsn-1065	92	31	[	[	X
hsn-1065	92	32	4,9	4,9	NUM
hsn-1065	92	33	]	]	PUNCT
hsn-1065	92	34	.	.	PUNCT
hsn-1065	93	1	a	a	DET
hsn-1065	93	2	study	study	NOUN
hsn-1065	93	3	by	by	ADP
hsn-1065	93	4	madjid	madjid	PROPN
hsn-1065	93	5	et	et	PROPN
hsn-1065	93	6	al	al	PROPN
hsn-1065	93	7	.	.	PROPN
hsn-1065	93	8	also	also	ADV
hsn-1065	93	9	established	establish	VERB
hsn-1065	93	10	that	that	SCONJ
hsn-1065	93	11	higher	high	ADJ
hsn-1065	93	12	leukocyte	leukocyte	NOUN
hsn-1065	93	13	counts	count	NOUN
hsn-1065	93	14	were	be	AUX
hsn-1065	93	15	linked	link	VERB
hsn-1065	93	16	to	to	ADP
hsn-1065	93	17	increased	increase	VERB
hsn-1065	93	18	coronary	coronary	ADJ
hsn-1065	93	19	heart	heart	NOUN
hsn-1065	93	20	disease	disease	NOUN
hsn-1065	93	21	risk	risk	NOUN
hsn-1065	93	22	and	and	CCONJ
hsn-1065	93	23	adverse	adverse	ADJ
hsn-1065	93	24	outcomes	outcome	NOUN
hsn-1065	93	25	[	[	X
hsn-1065	93	26	10].on	10].on	NUM
hsn-1065	93	27	the	the	DET
hsn-1065	93	28	other	other	ADJ
hsn-1065	93	29	hand	hand	NOUN
hsn-1065	93	30	,	,	PUNCT
hsn-1065	93	31	reduced	reduce	VERB
hsn-1065	93	32	rbc	rbc	PROPN
hsn-1065	93	33	levels	level	NOUN
hsn-1065	93	34	in	in	ADP
hsn-1065	93	35	cad	cad	PROPN
hsn-1065	93	36	patients	patient	NOUN
hsn-1065	93	37	,	,	PUNCT
hsn-1065	93	38	although	although	SCONJ
hsn-1065	93	39	sometimes	sometimes	ADV
hsn-1065	93	40	overlooked	overlook	VERB
hsn-1065	93	41	,	,	PUNCT
hsn-1065	93	42	can	can	AUX
hsn-1065	93	43	aggravate	aggravate	VERB
hsn-1065	93	44	myocardial	myocardial	ADJ
hsn-1065	93	45	ischemia	ischemia	NOUN
hsn-1065	93	46	by	by	ADP
hsn-1065	93	47	impairing	impair	VERB
hsn-1065	93	48	oxygen	oxygen	NOUN
hsn-1065	93	49	delivery	delivery	NOUN
hsn-1065	94	1	[	[	X
hsn-1065	94	2	5	5	NUM
hsn-1065	94	3	]	]	PUNCT
hsn-1065	94	4	.	.	PUNCT
hsn-1065	95	1	anemia	anemia	NOUN
hsn-1065	95	2	has	have	AUX
hsn-1065	95	3	previously	previously	ADV
hsn-1065	95	4	been	be	AUX
hsn-1065	95	5	associated	associate	VERB
hsn-1065	95	6	with	with	ADP
hsn-1065	95	7	poor	poor	ADJ
hsn-1065	95	8	prognosis	prognosis	NOUN
hsn-1065	95	9	in	in	ADP
hsn-1065	95	10	cad	cad	PROPN
hsn-1065	95	11	,	,	PUNCT
hsn-1065	95	12	particularly	particularly	ADV
hsn-1065	95	13	in	in	ADP
hsn-1065	95	14	elderly	elderly	ADJ
hsn-1065	95	15	and	and	CCONJ
hsn-1065	95	16	female	female	ADJ
hsn-1065	95	17	patients	patient	NOUN
hsn-1065	95	18	[	[	X
hsn-1065	95	19	11	11	NUM
hsn-1065	95	20	]	]	PUNCT
hsn-1065	95	21	interestingly	interestingly	ADV
hsn-1065	95	22	,	,	PUNCT
hsn-1065	95	23	while	while	SCONJ
hsn-1065	95	24	aptt	aptt	PROPN
hsn-1065	95	25	was	be	AUX
hsn-1065	95	26	significantly	significantly	ADV
hsn-1065	95	27	higher	high	ADJ
hsn-1065	95	28	in	in	ADP
hsn-1065	95	29	males	male	NOUN
hsn-1065	95	30	,	,	PUNCT
hsn-1065	95	31	wbc	wbc	PROPN
hsn-1065	95	32	was	be	AUX
hsn-1065	95	33	insignificantly	insignificantly	ADV
hsn-1065	95	34	lower	low	ADJ
hsn-1065	95	35	,	,	PUNCT
hsn-1065	95	36	and	and	CCONJ
hsn-1065	95	37	rbc	rbc	PROPN
hsn-1065	95	38	insignificantly	insignificantly	ADV
hsn-1065	95	39	higher	higher	ADV
hsn-1065	95	40	compared	compare	VERB
hsn-1065	95	41	to	to	ADP
hsn-1065	95	42	females	female	NOUN
hsn-1065	95	43	.	.	PUNCT
hsn-1065	96	1	these	these	DET
hsn-1065	96	2	gender	gender	NOUN
hsn-1065	96	3	variations	variation	NOUN
hsn-1065	96	4	are	be	AUX
hsn-1065	96	5	similar	similar	ADJ
hsn-1065	96	6	to	to	ADP
hsn-1065	96	7	those	those	PRON
hsn-1065	96	8	noted	note	VERB
hsn-1065	96	9	in	in	ADP
hsn-1065	96	10	a	a	DET
hsn-1065	96	11	study	study	NOUN
hsn-1065	96	12	by	by	ADP
hsn-1065	96	13	pradhan	pradhan	PROPN
hsn-1065	96	14	et	et	PROPN
hsn-1065	96	15	al	al	PROPN
hsn-1065	96	16	.	.	PROPN
hsn-1065	96	17	,	,	PUNCT
hsn-1065	96	18	who	who	PRON
hsn-1065	96	19	reported	report	VERB
hsn-1065	96	20	sex	sex	NOUN
hsn-1065	96	21	differences	difference	NOUN
hsn-1065	96	22	in	in	ADP
hsn-1065	96	23	inflammatory	inflammatory	ADJ
hsn-1065	96	24	and	and	CCONJ
hsn-1065	96	25	coagulation	coagulation	NOUN
hsn-1065	96	26	profiles	profile	NOUN
hsn-1065	96	27	among	among	ADP
hsn-1065	96	28	cardiovascular	cardiovascular	ADJ
hsn-1065	96	29	patients	patient	NOUN
hsn-1065	96	30	[	[	X
hsn-1065	96	31	6	6	NUM
hsn-1065	96	32	]	]	PUNCT
hsn-1065	96	33	.	.	PUNCT
hsn-1065	97	1	ijo	ijo	PROPN
hsn-1065	97	2	journals	journal	NOUN
hsn-1065	97	3	volume	volume	NOUN
hsn-1065	97	4	08	08	NUM
hsn-1065	98	1	|	|	ADV
hsn-1065	98	2	issue	issue	VERB
hsn-1065	98	3	04	04	NUM
hsn-1065	99	1	|	|	CCONJ
hsn-1065	99	2	april	april	PROPN
hsn-1065	99	3	2025	2025	NUM
hsn-1065	100	1	|	|	ADV
hsn-1065	100	2	https://ijojournals.com/index.php/hsn/index	https://ijojournals.com/index.php/hsn/index	NOUN
hsn-1065	100	3	7	7	NUM
hsn-1065	100	4	ijo	ijo	PROPN
hsn-1065	100	5	international	international	PROPN
hsn-1065	100	6	journal	journal	PROPN
hsn-1065	100	7	of	of	ADP
hsn-1065	100	8	health	health	PROPN
hsn-1065	100	9	sciences	sciences	PROPN
hsn-1065	100	10	and	and	CCONJ
hsn-1065	100	11	nursing	nursing	NOUN
hsn-1065	100	12	(	(	PUNCT
hsn-1065	100	13	issn	issn	PROPN
hsn-1065	100	14	:	:	PUNCT
hsn-1065	100	15	2814	2814	NUM
hsn-1065	100	16	-	-	SYM
hsn-1065	100	17	2098	2098	NUM
hsn-1065	100	18	)	)	PUNCT
hsn-1065	100	19	chinedu	chinedu	NOUN
hsn-1065	100	20	-	-	PUNCT
hsn-1065	100	21	madu	madu	NOUN
hsn-1065	100	22	jane	jane	NOUN
hsn-1065	100	23	u	u	NOUN
hsn-1065	100	24	1	1	NUM
hsn-1065	100	25	*	*	PUNCT
hsn-1065	100	26	https://ijojournals.com/	https://ijojournals.com/	NOUN
hsn-1065	100	27	volume	volume	NOUN
hsn-1065	100	28	08	08	NUM
hsn-1065	100	29	||	||	PROPN
hsn-1065	100	30	issue	issue	NOUN
hsn-1065	100	31	04	04	NUM
hsn-1065	100	32	||	||	NOUN
hsn-1065	100	33	april	april	PROPN
hsn-1065	100	34	,	,	PUNCT
hsn-1065	100	35	2025	2025	NUM
hsn-1065	100	36	||	||	PUNCT
hsn-1065	101	1	“	"	PUNCT
hsn-1065	101	2	studies	study	NOUN
hsn-1065	101	3	on	on	ADP
hsn-1065	101	4	activated	activate	VERB
hsn-1065	101	5	partial	partial	ADJ
hsn-1065	101	6	thromboplastin	thromboplastin	NOUN
hsn-1065	101	7	time	time	NOUN
hsn-1065	101	8	,	,	PUNCT
hsn-1065	101	9	red	red	ADJ
hsn-1065	101	10	and	and	CCONJ
hsn-1065	101	11	white	white	ADJ
hsn-1065	101	12	blood	blood	NOUN
hsn-1065	101	13	cell	cell	NOUN
hsn-1065	101	14	counts	count	NOUN
hsn-1065	101	15	in	in	ADP
hsn-1065	101	16	coronary	coronary	ADJ
hsn-1065	101	17	artery	artery	NOUN
hsn-1065	101	18	disease	disease	NOUN
hsn-1065	101	19	in	in	ADP
hsn-1065	101	20	owerri	owerri	PROPN
hsn-1065	101	21	,	,	PUNCT
hsn-1065	101	22	nigeria	nigeria	PROPN
hsn-1065	101	23	..	..	PUNCT
hsn-1065	101	24	"	"	PUNCT
hsn-1065	101	25	correlation	correlation	NOUN
hsn-1065	101	26	analysis	analysis	NOUN
hsn-1065	101	27	in	in	ADP
hsn-1065	101	28	this	this	DET
hsn-1065	101	29	study	study	NOUN
hsn-1065	101	30	did	do	AUX
hsn-1065	101	31	not	not	PART
hsn-1065	101	32	show	show	VERB
hsn-1065	101	33	a	a	DET
hsn-1065	101	34	significant	significant	ADJ
hsn-1065	101	35	relationship	relationship	NOUN
hsn-1065	101	36	between	between	ADP
hsn-1065	101	37	aptt	aptt	PROPN
hsn-1065	101	38	,	,	PUNCT
hsn-1065	101	39	rbc	rbc	PROPN
hsn-1065	101	40	,	,	PUNCT
hsn-1065	101	41	and	and	CCONJ
hsn-1065	101	42	wbc	wbc	PROPN
hsn-1065	101	43	,	,	PUNCT
hsn-1065	101	44	indicating	indicate	VERB
hsn-1065	101	45	that	that	SCONJ
hsn-1065	101	46	these	these	DET
hsn-1065	101	47	parameters	parameter	NOUN
hsn-1065	101	48	may	may	AUX
hsn-1065	101	49	contribute	contribute	VERB
hsn-1065	101	50	independently	independently	ADV
hsn-1065	101	51	to	to	ADP
hsn-1065	101	52	cad	cad	PROPN
hsn-1065	101	53	pathophysiology	pathophysiology	NOUN
hsn-1065	101	54	.	.	PUNCT
hsn-1065	102	1	this	this	DET
hsn-1065	102	2	independence	independence	NOUN
hsn-1065	102	3	reflects	reflect	VERB
hsn-1065	102	4	the	the	DET
hsn-1065	102	5	multifactorial	multifactorial	ADJ
hsn-1065	102	6	nature	nature	NOUN
hsn-1065	102	7	of	of	ADP
hsn-1065	102	8	cad	cad	PROPN
hsn-1065	102	9	,	,	PUNCT
hsn-1065	102	10	where	where	SCONJ
hsn-1065	102	11	inflammation	inflammation	NOUN
hsn-1065	102	12	,	,	PUNCT
hsn-1065	102	13	anemia	anemia	NOUN
hsn-1065	102	14	,	,	PUNCT
hsn-1065	102	15	and	and	CCONJ
hsn-1065	102	16	coagulopathy	coagulopathy	ADJ
hsn-1065	102	17	may	may	AUX
hsn-1065	102	18	all	all	PRON
hsn-1065	102	19	simultaneously	simultaneously	ADV
hsn-1065	102	20	affect	affect	VERB
hsn-1065	102	21	patient	patient	ADJ
hsn-1065	102	22	outcomes	outcome	NOUN
hsn-1065	102	23	[	[	X
hsn-1065	102	24	12	12	NUM
hsn-1065	102	25	]	]	PUNCT
hsn-1065	102	26	.	.	PUNCT
hsn-1065	103	1	in	in	ADP
hsn-1065	103	2	summary	summary	NOUN
hsn-1065	103	3	,	,	PUNCT
hsn-1065	103	4	the	the	DET
hsn-1065	103	5	findings	finding	NOUN
hsn-1065	103	6	support	support	VERB
hsn-1065	103	7	previous	previous	ADJ
hsn-1065	103	8	evidence	evidence	NOUN
hsn-1065	103	9	of	of	ADP
hsn-1065	103	10	hematological	hematological	ADJ
hsn-1065	103	11	disturbances	disturbance	NOUN
hsn-1065	103	12	in	in	ADP
hsn-1065	103	13	cad	cad	PROPN
hsn-1065	103	14	and	and	CCONJ
hsn-1065	103	15	suggest	suggest	VERB
hsn-1065	103	16	the	the	DET
hsn-1065	103	17	need	need	NOUN
hsn-1065	103	18	for	for	ADP
hsn-1065	103	19	routine	routine	ADJ
hsn-1065	103	20	hematologic	hematologic	NOUN
hsn-1065	103	21	assessments	assessment	NOUN
hsn-1065	103	22	in	in	ADP
hsn-1065	103	23	cad	cad	PROPN
hsn-1065	103	24	management	management	NOUN
hsn-1065	103	25	.	.	PUNCT
hsn-1065	104	1	further	far	ADV
hsn-1065	104	2	large	large	ADJ
hsn-1065	104	3	-	-	PUNCT
hsn-1065	104	4	scale	scale	NOUN
hsn-1065	104	5	studies	study	NOUN
hsn-1065	104	6	are	be	AUX
hsn-1065	104	7	necessary	necessary	ADJ
hsn-1065	104	8	to	to	PART
hsn-1065	104	9	explore	explore	VERB
hsn-1065	104	10	these	these	DET
hsn-1065	104	11	associations	association	NOUN
hsn-1065	104	12	and	and	CCONJ
hsn-1065	104	13	validate	validate	VERB
hsn-1065	104	14	their	their	PRON
hsn-1065	104	15	prognostic	prognostic	ADJ
hsn-1065	104	16	significance	significance	NOUN
hsn-1065	104	17	.	.	PUNCT
hsn-1065	105	1	5	5	X
hsn-1065	105	2	.	.	X
hsn-1065	105	3	conclusion	conclusion	NOUN
hsn-1065	105	4	in	in	ADP
hsn-1065	105	5	conclusion	conclusion	NOUN
hsn-1065	105	6	,	,	PUNCT
hsn-1065	105	7	the	the	DET
hsn-1065	105	8	study	study	NOUN
hsn-1065	105	9	's	's	PART
hsn-1065	105	10	findings	finding	NOUN
hsn-1065	105	11	highlight	highlight	VERB
hsn-1065	105	12	significant	significant	ADJ
hsn-1065	105	13	hematological	hematological	ADJ
hsn-1065	105	14	and	and	CCONJ
hsn-1065	105	15	haemostatic	haemostatic	ADJ
hsn-1065	105	16	alterations	alteration	NOUN
hsn-1065	105	17	in	in	ADP
hsn-1065	105	18	cad	cad	PROPN
hsn-1065	105	19	patients	patient	NOUN
hsn-1065	105	20	,	,	PUNCT
hsn-1065	105	21	with	with	ADP
hsn-1065	105	22	notable	notable	ADJ
hsn-1065	105	23	gender	gender	NOUN
hsn-1065	105	24	-	-	PUNCT
hsn-1065	105	25	based	base	VERB
hsn-1065	105	26	differences	difference	NOUN
hsn-1065	105	27	.	.	PUNCT
hsn-1065	106	1	these	these	DET
hsn-1065	106	2	insights	insight	NOUN
hsn-1065	106	3	underscore	underscore	VERB
hsn-1065	106	4	the	the	DET
hsn-1065	106	5	importance	importance	NOUN
hsn-1065	106	6	of	of	ADP
hsn-1065	106	7	incorporating	incorporate	VERB
hsn-1065	106	8	hematological	hematological	ADJ
hsn-1065	106	9	assessments	assessment	NOUN
hsn-1065	106	10	into	into	ADP
hsn-1065	106	11	the	the	DET
hsn-1065	106	12	clinical	clinical	ADJ
hsn-1065	106	13	management	management	NOUN
hsn-1065	106	14	of	of	ADP
hsn-1065	106	15	cad	cad	PROPN
hsn-1065	106	16	and	and	CCONJ
hsn-1065	106	17	suggest	suggest	VERB
hsn-1065	106	18	avenues	avenue	NOUN
hsn-1065	106	19	for	for	ADP
hsn-1065	106	20	personalized	personalize	VERB
hsn-1065	106	21	therapeutic	therapeutic	ADJ
hsn-1065	106	22	strategies	strategy	NOUN
hsn-1065	106	23	.	.	PUNCT
hsn-1065	107	1	further	further	ADJ
hsn-1065	107	2	research	research	NOUN
hsn-1065	107	3	is	be	AUX
hsn-1065	107	4	warranted	warrant	VERB
hsn-1065	107	5	to	to	PART
hsn-1065	107	6	elucidate	elucidate	VERB
hsn-1065	107	7	the	the	DET
hsn-1065	107	8	mechanisms	mechanism	NOUN
hsn-1065	107	9	underlying	underlie	VERB
hsn-1065	107	10	these	these	DET
hsn-1065	107	11	alterations	alteration	NOUN
hsn-1065	107	12	and	and	CCONJ
hsn-1065	107	13	their	their	PRON
hsn-1065	107	14	implications	implication	NOUN
hsn-1065	107	15	for	for	ADP
hsn-1065	107	16	cad	cad	NOUN
hsn-1065	107	17	prognosis	prognosis	NOUN
hsn-1065	107	18	and	and	CCONJ
hsn-1065	107	19	treatment	treatment	NOUN
hsn-1065	107	20	.	.	PUNCT
hsn-1065	108	1	references	reference	NOUN
hsn-1065	108	2	1	1	NUM
hsn-1065	108	3	.	.	PUNCT
hsn-1065	108	4	roth	roth	PROPN
hsn-1065	108	5	ga	ga	PROPN
hsn-1065	108	6	,	,	PUNCT
hsn-1065	108	7	mensah	mensah	PROPN
hsn-1065	108	8	ga	ga	PROPN
hsn-1065	108	9	,	,	PUNCT
hsn-1065	108	10	johnson	johnson	PROPN
hsn-1065	108	11	co	co	PROPN
hsn-1065	108	12	,	,	PUNCT
hsn-1065	108	13	et	et	PROPN
hsn-1065	108	14	al	al	PROPN
hsn-1065	108	15	.	.	PUNCT
hsn-1065	109	1	global	global	ADJ
hsn-1065	109	2	burden	burden	NOUN
hsn-1065	109	3	of	of	ADP
hsn-1065	109	4	cardiovascular	cardiovascular	ADJ
hsn-1065	109	5	diseases	disease	NOUN
hsn-1065	109	6	and	and	CCONJ
hsn-1065	109	7	risk	risk	NOUN
hsn-1065	109	8	factors	factor	NOUN
hsn-1065	109	9	,	,	PUNCT
hsn-1065	109	10	1990–2019	1990–2019	NUM
hsn-1065	109	11	:	:	PUNCT
hsn-1065	109	12	update	update	NOUN
hsn-1065	109	13	from	from	ADP
hsn-1065	109	14	the	the	DET
hsn-1065	109	15	gbd	gbd	NOUN
hsn-1065	109	16	2019	2019	NUM
hsn-1065	109	17	study	study	NOUN
hsn-1065	109	18	.	.	PUNCT
hsn-1065	110	1	j	j	PROPN
hsn-1065	110	2	am	be	AUX
hsn-1065	110	3	collcardiol	collcardiol	ADJ
hsn-1065	110	4	.	.	PUNCT
hsn-1065	111	1	2020;76(25):2982	2020;76(25):2982	X
hsn-1065	111	2	–	–	PUNCT
hsn-1065	111	3	3021	3021	NUM
hsn-1065	111	4	.	.	PUNCT
hsn-1065	112	1	2	2	X
hsn-1065	112	2	.	.	X
hsn-1065	112	3	singh	singh	PROPN
hsn-1065	112	4	rb	rb	PROPN
hsn-1065	112	5	,	,	PUNCT
hsn-1065	112	6	mengi	mengi	PROPN
hsn-1065	112	7	sa	sa	PROPN
hsn-1065	112	8	,	,	PUNCT
hsn-1065	112	9	xu	xu	PROPN
hsn-1065	112	10	yj	yj	PROPN
hsn-1065	112	11	,	,	PUNCT
hsn-1065	112	12	arneja	arneja	ADV
hsn-1065	112	13	as	as	ADP
hsn-1065	112	14	,	,	PUNCT
hsn-1065	112	15	dhalla	dhalla	NOUN
hsn-1065	112	16	ns	ns	NOUN
hsn-1065	112	17	.	.	PROPN
hsn-1065	112	18	pathogenesis	pathogenesis	NOUN
hsn-1065	112	19	of	of	ADP
hsn-1065	112	20	atherosclerosis	atherosclerosis	NOUN
hsn-1065	112	21	:	:	PUNCT
hsn-1065	112	22	a	a	DET
hsn-1065	112	23	multifactorial	multifactorial	ADJ
hsn-1065	112	24	process	process	NOUN
hsn-1065	112	25	.	.	PUNCT
hsn-1065	113	1	expclincardiol	expclincardiol	NOUN
hsn-1065	113	2	.	.	PUNCT
hsn-1065	114	1	2002;7(1):40–53	2002;7(1):40–53	NUM
hsn-1065	114	2	.	.	PUNCT
hsn-1065	115	1	3	3	X
hsn-1065	115	2	.	.	X
hsn-1065	115	3	sotoudehanvari	sotoudehanvari	PROPN
hsn-1065	115	4	m	m	PROPN
hsn-1065	115	5	,	,	PUNCT
hsn-1065	115	6	tavakoli	tavakoli	PROPN
hsn-1065	115	7	m	m	PROPN
hsn-1065	115	8	,	,	PUNCT
hsn-1065	115	9	lotfi	lotfi	PROPN
hsn-1065	115	10	-	-	PUNCT
hsn-1065	115	11	tokaldany	tokaldany	NOUN
hsn-1065	115	12	m	m	PROPN
hsn-1065	115	13	,	,	PUNCT
hsn-1065	115	14	et	et	PROPN
hsn-1065	115	15	al	al	PROPN
hsn-1065	115	16	.	.	PUNCT
hsn-1065	116	1	coronary	coronary	ADJ
hsn-1065	116	2	artery	artery	NOUN
hsn-1065	116	3	disease	disease	NOUN
hsn-1065	116	4	presentation	presentation	NOUN
hsn-1065	116	5	and	and	CCONJ
hsn-1065	116	6	its	its	PRON
hsn-1065	116	7	association	association	NOUN
hsn-1065	116	8	with	with	ADP
hsn-1065	116	9	shortened	shorten	VERB
hsn-1065	116	10	activated	activate	VERB
hsn-1065	116	11	partial	partial	ADJ
hsn-1065	116	12	thromboplastin	thromboplastin	NOUN
hsn-1065	116	13	time	time	NOUN
hsn-1065	116	14	.	.	PUNCT
hsn-1065	117	1	j	j	PROPN
hsn-1065	117	2	tehran	tehran	PROPN
hsn-1065	117	3	heart	heart	PROPN
hsn-1065	117	4	cent	cent	NOUN
hsn-1065	117	5	.	.	PUNCT
hsn-1065	118	1	2018;13(1):1–5	2018;13(1):1–5	NOUN
hsn-1065	118	2	.	.	PUNCT
hsn-1065	119	1	4	4	X
hsn-1065	119	2	.	.	X
hsn-1065	119	3	cannon	cannon	NOUN
hsn-1065	119	4	cp	cp	PROPN
hsn-1065	119	5	,	,	PUNCT
hsn-1065	119	6	mccabe	mccabe	PROPN
hsn-1065	119	7	ch	ch	PROPN
hsn-1065	119	8	,	,	PUNCT
hsn-1065	119	9	wilcox	wilcox	PROPN
hsn-1065	119	10	rg	rg	PROPN
hsn-1065	119	11	,	,	PUNCT
hsn-1065	119	12	et	et	PROPN
hsn-1065	119	13	al	al	PROPN
hsn-1065	119	14	.	.	PROPN
hsn-1065	119	15	association	association	PROPN
hsn-1065	119	16	of	of	ADP
hsn-1065	119	17	white	white	ADJ
hsn-1065	119	18	blood	blood	NOUN
hsn-1065	119	19	cell	cell	NOUN
hsn-1065	119	20	count	count	NOUN
hsn-1065	119	21	with	with	ADP
hsn-1065	119	22	increased	increase	VERB
hsn-1065	119	23	mortality	mortality	NOUN
hsn-1065	119	24	in	in	ADP
hsn-1065	119	25	acute	acute	ADJ
hsn-1065	119	26	myocardial	myocardial	ADJ
hsn-1065	119	27	infarction	infarction	NOUN
hsn-1065	119	28	and	and	CCONJ
hsn-1065	119	29	unstable	unstable	ADJ
hsn-1065	119	30	angina	angina	NOUN
hsn-1065	119	31	pectoris	pectoris	ADJ
hsn-1065	119	32	.	.	PUNCT
hsn-1065	120	1	am	be	AUX
hsn-1065	120	2	j	j	PROPN
hsn-1065	120	3	cardiol	cardiol	NOUN
hsn-1065	120	4	.	.	PUNCT
hsn-1065	121	1	2001;87(5):636–639	2001;87(5):636–639	NUM
hsn-1065	121	2	.	.	PROPN
hsn-1065	122	1	5	5	NUM
hsn-1065	122	2	.	.	X
hsn-1065	122	3	sabatine	sabatine	PROPN
hsn-1065	122	4	ms	ms	PROPN
hsn-1065	122	5	,	,	PUNCT
hsn-1065	122	6	morrow	morrow	PROPN
hsn-1065	122	7	da	da	PROPN
hsn-1065	122	8	,	,	PUNCT
hsn-1065	122	9	giugliano	giugliano	ADJ
hsn-1065	122	10	rp	rp	NOUN
hsn-1065	122	11	,	,	PUNCT
hsn-1065	122	12	et	et	PROPN
hsn-1065	122	13	al	al	PROPN
hsn-1065	122	14	.	.	PROPN
hsn-1065	122	15	association	association	PROPN
hsn-1065	122	16	of	of	ADP
hsn-1065	122	17	hemoglobin	hemoglobin	NOUN
hsn-1065	122	18	levels	level	NOUN
hsn-1065	122	19	with	with	ADP
hsn-1065	122	20	clinical	clinical	ADJ
hsn-1065	122	21	outcomes	outcome	NOUN
hsn-1065	122	22	in	in	ADP
hsn-1065	122	23	acute	acute	ADJ
hsn-1065	122	24	coronary	coronary	ADJ
hsn-1065	122	25	syndromes	syndrome	NOUN
hsn-1065	122	26	.	.	PUNCT
hsn-1065	123	1	circulation	circulation	NOUN
hsn-1065	123	2	.	.	PUNCT
hsn-1065	124	1	2005;111(16):2042–2049	2005;111(16):2042–2049	NUM
hsn-1065	124	2	.	.	PUNCT
hsn-1065	124	3	ijo	ijo	PROPN
hsn-1065	124	4	journals	journal	NOUN
hsn-1065	124	5	volume	volume	NOUN
hsn-1065	124	6	08	08	NUM
hsn-1065	125	1	|	|	ADV
hsn-1065	125	2	issue	issue	VERB
hsn-1065	125	3	04	04	NUM
hsn-1065	126	1	|	|	CCONJ
hsn-1065	126	2	april	april	PROPN
hsn-1065	126	3	2025	2025	NUM
hsn-1065	127	1	|	|	ADV
hsn-1065	127	2	https://ijojournals.com/index.php/hsn/index	https://ijojournals.com/index.php/hsn/index	NOUN
hsn-1065	127	3	8	8	NUM
hsn-1065	127	4	ijo	ijo	PROPN
hsn-1065	127	5	international	international	PROPN
hsn-1065	127	6	journal	journal	PROPN
hsn-1065	127	7	of	of	ADP
hsn-1065	127	8	health	health	PROPN
hsn-1065	127	9	sciences	sciences	PROPN
hsn-1065	127	10	and	and	CCONJ
hsn-1065	127	11	nursing	nursing	NOUN
hsn-1065	127	12	(	(	PUNCT
hsn-1065	127	13	issn	issn	PROPN
hsn-1065	127	14	:	:	PUNCT
hsn-1065	127	15	2814	2814	NUM
hsn-1065	127	16	-	-	SYM
hsn-1065	127	17	2098	2098	NUM
hsn-1065	127	18	)	)	PUNCT
hsn-1065	127	19	chinedu	chinedu	NOUN
hsn-1065	127	20	-	-	PUNCT
hsn-1065	127	21	madu	madu	NOUN
hsn-1065	127	22	jane	jane	NOUN
hsn-1065	127	23	u	u	NOUN
hsn-1065	127	24	1	1	NUM
hsn-1065	127	25	*	*	PUNCT
hsn-1065	127	26	https://ijojournals.com/	https://ijojournals.com/	NOUN
hsn-1065	127	27	volume	volume	NOUN
hsn-1065	127	28	08	08	NUM
hsn-1065	127	29	||	||	PROPN
hsn-1065	127	30	issue	issue	NOUN
hsn-1065	127	31	04	04	NUM
hsn-1065	127	32	||	||	NOUN
hsn-1065	127	33	april	april	PROPN
hsn-1065	127	34	,	,	PUNCT
hsn-1065	127	35	2025	2025	NUM
hsn-1065	127	36	||	||	PUNCT
hsn-1065	128	1	“	"	PUNCT
hsn-1065	128	2	studies	study	NOUN
hsn-1065	128	3	on	on	ADP
hsn-1065	128	4	activated	activate	VERB
hsn-1065	128	5	partial	partial	ADJ
hsn-1065	128	6	thromboplastin	thromboplastin	NOUN
hsn-1065	128	7	time	time	NOUN
hsn-1065	128	8	,	,	PUNCT
hsn-1065	128	9	red	red	ADJ
hsn-1065	128	10	and	and	CCONJ
hsn-1065	128	11	white	white	ADJ
hsn-1065	128	12	blood	blood	NOUN
hsn-1065	128	13	cell	cell	NOUN
hsn-1065	128	14	counts	count	NOUN
hsn-1065	128	15	in	in	ADP
hsn-1065	128	16	coronary	coronary	ADJ
hsn-1065	128	17	artery	artery	NOUN
hsn-1065	128	18	disease	disease	NOUN
hsn-1065	128	19	in	in	ADP
hsn-1065	128	20	owerri	owerri	PROPN
hsn-1065	128	21	,	,	PUNCT
hsn-1065	128	22	nigeria	nigeria	PROPN
hsn-1065	128	23	..	..	PUNCT
hsn-1065	128	24	"	"	PUNCT
hsn-1065	129	1	6	6	NUM
hsn-1065	129	2	.	.	PUNCT
hsn-1065	129	3	pradhan	pradhan	PROPN
hsn-1065	129	4	ad	ad	NOUN
hsn-1065	129	5	,	,	PUNCT
hsn-1065	129	6	manson	manson	PROPN
hsn-1065	129	7	je	je	PROPN
hsn-1065	129	8	,	,	PUNCT
hsn-1065	129	9	rifai	rifai	PROPN
hsn-1065	129	10	n	n	CCONJ
hsn-1065	129	11	,	,	PUNCT
hsn-1065	129	12	buring	bur	VERB
hsn-1065	129	13	je	je	PROPN
hsn-1065	129	14	,	,	PUNCT
hsn-1065	129	15	ridker	ridker	PROPN
hsn-1065	129	16	pm	pm	PROPN
hsn-1065	129	17	.	.	PUNCT
hsn-1065	130	1	c	c	X
hsn-1065	130	2	-	-	PUNCT
hsn-1065	130	3	reactive	reactive	ADJ
hsn-1065	130	4	protein	protein	NOUN
hsn-1065	130	5	,	,	PUNCT
hsn-1065	130	6	interleukin	interleukin	NOUN
hsn-1065	130	7	6	6	NUM
hsn-1065	130	8	,	,	PUNCT
hsn-1065	130	9	and	and	CCONJ
hsn-1065	130	10	risk	risk	NOUN
hsn-1065	130	11	of	of	ADP
hsn-1065	130	12	developing	develop	VERB
hsn-1065	130	13	type	type	NOUN
hsn-1065	130	14	2	2	NUM
hsn-1065	130	15	diabetes	diabetes	NOUN
hsn-1065	130	16	mellitus	mellitus	NOUN
hsn-1065	130	17	.	.	PUNCT
hsn-1065	131	1	jama	jama	PROPN
hsn-1065	131	2	.	.	PUNCT
hsn-1065	132	1	2001;286(3):327–334	2001;286(3):327–334	NUM
hsn-1065	132	2	.	.	NOUN
hsn-1065	132	3	7	7	X
hsn-1065	132	4	.	.	X
hsn-1065	132	5	sharma	sharma	PROPN
hsn-1065	132	6	r	r	PROPN
hsn-1065	132	7	,	,	PUNCT
hsn-1065	132	8	goyal	goyal	PROPN
hsn-1065	132	9	a	a	X
hsn-1065	132	10	,	,	PUNCT
hsn-1065	132	11	sinha	sinha	PROPN
hsn-1065	132	12	m	m	PROPN
hsn-1065	132	13	,	,	PUNCT
hsn-1065	132	14	et	et	PROPN
hsn-1065	132	15	al	al	PROPN
hsn-1065	132	16	.	.	PUNCT
hsn-1065	133	1	coagulation	coagulation	NOUN
hsn-1065	133	2	profile	profile	NOUN
hsn-1065	133	3	in	in	ADP
hsn-1065	133	4	patients	patient	NOUN
hsn-1065	133	5	of	of	ADP
hsn-1065	133	6	ischemic	ischemic	ADJ
hsn-1065	133	7	heart	heart	NOUN
hsn-1065	133	8	disease	disease	NOUN
hsn-1065	133	9	with	with	ADP
hsn-1065	133	10	reference	reference	NOUN
hsn-1065	133	11	to	to	ADP
hsn-1065	133	12	activated	activate	VERB
hsn-1065	133	13	partial	partial	ADJ
hsn-1065	133	14	thromboplastin	thromboplastin	NOUN
hsn-1065	133	15	time	time	NOUN
hsn-1065	133	16	.	.	PUNCT
hsn-1065	134	1	int	int	PROPN
hsn-1065	134	2	j	j	PROPN
hsn-1065	134	3	adv	adv	PROPN
hsn-1065	134	4	med	me	VERB
hsn-1065	134	5	.	.	PUNCT
hsn-1065	135	1	2018;5(3):612–615	2018;5(3):612–615	NUM
hsn-1065	135	2	.	.	NOUN
hsn-1065	135	3	8	8	NUM
hsn-1065	135	4	.	.	PUNCT
hsn-1065	136	1	cushman	cushman	PROPN
hsn-1065	136	2	m	m	PROPN
hsn-1065	136	3	,	,	PUNCT
hsn-1065	136	4	glynn	glynn	PROPN
hsn-1065	136	5	rj	rj	PROPN
hsn-1065	136	6	,	,	PUNCT
hsn-1065	136	7	goldhaber	goldhaber	PROPN
hsn-1065	136	8	sz	sz	PROPN
hsn-1065	136	9	,	,	PUNCT
hsn-1065	136	10	et	et	PROPN
hsn-1065	136	11	al	al	PROPN
hsn-1065	136	12	.	.	PROPN
hsn-1065	136	13	hormone	hormone	NOUN
hsn-1065	136	14	replacement	replacement	NOUN
hsn-1065	136	15	therapy	therapy	NOUN
hsn-1065	136	16	and	and	CCONJ
hsn-1065	136	17	risk	risk	NOUN
hsn-1065	136	18	of	of	ADP
hsn-1065	136	19	venous	venous	ADJ
hsn-1065	136	20	thromboembolism	thromboembolism	NOUN
hsn-1065	136	21	in	in	ADP
hsn-1065	136	22	postmenopausal	postmenopausal	ADJ
hsn-1065	136	23	women	woman	NOUN
hsn-1065	136	24	.	.	PUNCT
hsn-1065	137	1	jama	jama	PROPN
hsn-1065	137	2	.	.	PUNCT
hsn-1065	138	1	2004;292(13):1573–158	2004;292(13):1573–158	NUM
hsn-1065	138	2	,	,	PUNCT
hsn-1065	138	3	9	9	NUM
hsn-1065	138	4	.	.	PUNCT
hsn-1065	139	1	libby	libby	PROPN
hsn-1065	139	2	p.	p.	PROPN
hsn-1065	139	3	inflammation	inflammation	NOUN
hsn-1065	139	4	in	in	ADP
hsn-1065	139	5	atherosclerosis.nature	atherosclerosis.nature	NOUN
hsn-1065	139	6	.	.	PUNCT
hsn-1065	140	1	2002;420(6917):868–874	2002;420(6917):868–874	NUM
hsn-1065	140	2	.	.	PUNCT
hsn-1065	141	1	10	10	NUM
hsn-1065	141	2	.	.	PUNCT
hsn-1065	142	1	madjid	madjid	PROPN
hsn-1065	142	2	m	m	PROPN
hsn-1065	142	3	,	,	PUNCT
hsn-1065	142	4	awan	awan	PROPN
hsn-1065	142	5	i	i	PROPN
hsn-1065	142	6	,	,	PUNCT
hsn-1065	142	7	willerson	willerson	PROPN
hsn-1065	142	8	jt	jt	PROPN
hsn-1065	142	9	,	,	PUNCT
hsn-1065	142	10	casscells	casscell	VERB
hsn-1065	142	11	sw	sw	PROPN
hsn-1065	142	12	.	.	PUNCT
hsn-1065	143	1	leukocyte	leukocyte	ADJ
hsn-1065	143	2	count	count	NOUN
hsn-1065	143	3	and	and	CCONJ
hsn-1065	143	4	coronary	coronary	ADJ
hsn-1065	143	5	heart	heart	NOUN
hsn-1065	143	6	disease	disease	NOUN
hsn-1065	143	7	:	:	PUNCT
hsn-1065	143	8	implications	implication	NOUN
hsn-1065	143	9	for	for	ADP
hsn-1065	143	10	risk	risk	NOUN
hsn-1065	143	11	assessment	assessment	NOUN
hsn-1065	143	12	.	.	PUNCT
hsn-1065	144	1	j	j	PROPN
hsn-1065	144	2	am	be	AUX
hsn-1065	144	3	collcardiol	collcardiol	ADJ
hsn-1065	144	4	.	.	PUNCT
hsn-1065	145	1	2004;44(10):1945–1956	2004;44(10):1945–1956	NUM
hsn-1065	145	2	.	.	PROPN
hsn-1065	146	1	11	11	NUM
hsn-1065	146	2	.	.	PUNCT
hsn-1065	147	1	sharma	sharma	PROPN
hsn-1065	147	2	r	r	PROPN
hsn-1065	147	3	,	,	PUNCT
hsn-1065	147	4	francis	francis	PROPN
hsn-1065	147	5	dp	dp	PROPN
hsn-1065	147	6	,	,	PUNCT
hsn-1065	147	7	pitt	pitt	PROPN
hsn-1065	147	8	b	b	PROPN
hsn-1065	147	9	,	,	PUNCT
hsn-1065	147	10	poole	poole	PROPN
hsn-1065	147	11	-	-	PUNCT
hsn-1065	147	12	wilson	wilson	PROPN
hsn-1065	147	13	pa	pa	PROPN
hsn-1065	147	14	,	,	PUNCT
hsn-1065	147	15	coats	coat	NOUN
hsn-1065	147	16	aj	aj	PROPN
hsn-1065	147	17	,	,	PUNCT
hsn-1065	147	18	anker	anker	PROPN
hsn-1065	147	19	sd	sd	PROPN
hsn-1065	147	20	.	.	PUNCT
hsn-1065	148	1	haemoglobin	haemoglobin	PROPN
hsn-1065	148	2	predicts	predict	VERB
hsn-1065	148	3	survival	survival	NOUN
hsn-1065	148	4	in	in	ADP
hsn-1065	148	5	patients	patient	NOUN
hsn-1065	148	6	with	with	ADP
hsn-1065	148	7	chronic	chronic	ADJ
hsn-1065	148	8	heart	heart	NOUN
hsn-1065	148	9	failure	failure	NOUN
hsn-1065	148	10	:	:	PUNCT
hsn-1065	148	11	a	a	DET
hsn-1065	148	12	substudy	substudy	NOUN
hsn-1065	148	13	of	of	ADP
hsn-1065	148	14	the	the	DET
hsn-1065	148	15	elite	elite	ADJ
hsn-1065	148	16	ii	ii	PROPN
hsn-1065	148	17	trial	trial	NOUN
hsn-1065	148	18	.	.	PUNCT
hsn-1065	149	1	eurheart	eurheart	PROPN
hsn-1065	149	2	j.	j.	PROPN
hsn-1065	149	3	2004;25(12):1021–1028	2004;25(12):1021–1028	PROPN
hsn-1065	149	4	.	.	PROPN
hsn-1065	149	5	12	12	NUM
hsn-1065	149	6	.	.	PUNCT
hsn-1065	150	1	packard	packard	PROPN
hsn-1065	150	2	rr	rr	PROPN
hsn-1065	150	3	,	,	PUNCT
hsn-1065	150	4	libby	libby	PROPN
hsn-1065	150	5	p.	p.	PROPN
hsn-1065	150	6	inflammation	inflammation	NOUN
hsn-1065	150	7	in	in	ADP
hsn-1065	150	8	atherosclerosis	atherosclerosis	NOUN
hsn-1065	150	9	:	:	PUNCT
hsn-1065	150	10	from	from	ADP
hsn-1065	150	11	vascular	vascular	ADJ
hsn-1065	150	12	biology	biology	NOUN
hsn-1065	150	13	to	to	PART
hsn-1065	150	14	biomarker	biomarker	VERB
hsn-1065	150	15	discovery	discovery	NOUN
hsn-1065	150	16	and	and	CCONJ
hsn-1065	150	17	risk	risk	NOUN
hsn-1065	150	18	prediction	prediction	NOUN
hsn-1065	150	19	.	.	PUNCT
hsn-1065	151	1	clin	clin	PROPN
hsn-1065	151	2	chem	chem	PROPN
hsn-1065	151	3	.	.	PUNCT
hsn-1065	152	1	2008;54(1):24–38	2008;54(1):24–38	X
hsn-1065	152	2	.	.	PUNCT
hsn-1065	152	3	ijo	ijo	PROPN
hsn-1065	152	4	journals	journal	NOUN
hsn-1065	152	5	volume	volume	NOUN
hsn-1065	152	6	08	08	NUM
hsn-1065	153	1	|	|	ADV
hsn-1065	153	2	issue	issue	VERB
hsn-1065	153	3	04	04	NUM
hsn-1065	154	1	|	|	CCONJ
hsn-1065	154	2	april	april	PROPN
hsn-1065	154	3	2025	2025	NUM
hsn-1065	154	4	|	|	ADV
hsn-1065	154	5	https://ijojournals.com/index.php/hsn/index	https://ijojournals.com/index.php/hsn/index	NOUN
hsn-1065	154	6	9	9	NUM
hsn-1065	154	7	2.5	2.5	NUM
hsn-1065	154	8	laboratory	laboratory	NOUN
hsn-1065	154	9	analysis	analysis	NOUN
hsn-1065	154	10	venous	venous	ADJ
hsn-1065	154	11	blood	blood	NOUN
hsn-1065	154	12	samples	sample	NOUN
hsn-1065	154	13	(	(	PUNCT
hsn-1065	154	14	5	5	NUM
hsn-1065	154	15	ml	ml	NOUN
hsn-1065	154	16	)	)	PUNCT
hsn-1065	154	17	were	be	AUX
hsn-1065	154	18	collected	collect	VERB
hsn-1065	154	19	aseptically	aseptically	ADV
hsn-1065	154	20	from	from	ADP
hsn-1065	154	21	each	each	DET
hsn-1065	154	22	participant	participant	NOUN
hsn-1065	154	23	.	.	PUNCT
hsn-1065	155	1	three	three	NUM
hsn-1065	155	2	milliliters	milliliter	NOUN
hsn-1065	155	3	(	(	PUNCT
hsn-1065	155	4	3	3	NUM
hsn-1065	155	5	ml	ml	NOUN
hsn-1065	155	6	)	)	PUNCT
hsn-1065	155	7	of	of	ADP
hsn-1065	155	8	the	the	DET
hsn-1065	155	9	blood	blood	NOUN
hsn-1065	155	10	weredispensed	weredispense	VERB
hsn-1065	155	11	into	into	ADP
hsn-1065	155	12	ethylenediaminetetraacetic	ethylenediaminetetraacetic	ADJ
hsn-1065	155	13	acid	acid	NOUN
hsn-1065	155	14	(	(	PUNCT
hsn-1065	155	15	edta	edta	NOUN
hsn-1065	155	16	)	)	PUNCT
hsn-1065	155	17	tubes	tube	NOUN
hsn-1065	155	18	for	for	ADP
hsn-1065	155	19	hematological	hematological	ADJ
hsn-1065	155	20	analysis	analysis	NOUN
hsn-1065	155	21	.	.	PUNCT
hsn-1065	156	1	the	the	DET
hsn-1065	156	2	remaining	remain	VERB
hsn-1065	156	3	2	2	NUM
hsn-1065	156	4	ml	ml	NOUN
hsn-1065	156	5	was	be	AUX
hsn-1065	156	6	used	use	VERB
hsn-1065	156	7	for	for	ADP
hsn-1065	156	8	haemostatic	haemostatic	ADJ
hsn-1065	156	9	analysis	analysis	NOUN
hsn-1065	156	10	.	.	PUNCT
hsn-1065	157	1	hematological	hematological	ADJ
hsn-1065	157	2	parameters	parameter	NOUN
hsn-1065	157	3	,	,	PUNCT
hsn-1065	157	4	including	include	VERB
hsn-1065	157	5	rbc	rbc	PROPN
hsn-1065	157	6	and	and	CCONJ
hsn-1065	157	7	wbc	wbc	PROPN
hsn-1065	157	8	counts	count	NOUN
hsn-1065	157	9	,	,	PUNCT
hsn-1065	157	10	were	be	AUX
hsn-1065	157	11	measured	measure	VERB
hsn-1065	157	12	using	use	VERB
hsn-1065	157	13	a	a	DET
hsn-1065	157	14	fully	fully	ADV
hsn-1065	157	15	automated	automate	VERB
hsn-1065	157	16	hematology	hematology	NOUN
hsn-1065	157	17	analyzer	analyzer	NOUN
hsn-1065	157	18	.	.	PUNCT
hsn-1065	158	1	aptt	aptt	PROPN
hsn-1065	158	2	was	be	AUX
hsn-1065	158	3	determined	determine	VERB
hsn-1065	158	4	using	use	VERB
hsn-1065	158	5	a	a	DET
hsn-1065	158	6	standard	standard	ADJ
hsn-1065	158	7	coagulometer	coagulometer	NOUN
hsn-1065	158	8	and	and	CCONJ
hsn-1065	158	9	commercial	commercial	ADJ
hsn-1065	158	10	reagents	reagent	NOUN
hsn-1065	158	11	according	accord	VERB
hsn-1065	158	12	to	to	ADP
hsn-1065	158	13	the	the	DET
hsn-1065	158	14	manufacturer	manufacturer	NOUN
hsn-1065	158	15	’s	’s	PART
hsn-1065	158	16	instructions	instruction	NOUN
hsn-1065	158	17	.	.	PUNCT
hsn-1065	159	1	2.6	2.6	NUM
hsn-1065	159	2	statistical	statistical	ADJ
hsn-1065	159	3	analysis	analysis	NOUN
hsn-1065	159	4	data	datum	NOUN
hsn-1065	159	5	were	be	AUX
hsn-1065	159	6	analyzed	analyze	VERB
hsn-1065	159	7	using	use	VERB
hsn-1065	159	8	the	the	DET
hsn-1065	159	9	statistical	statistical	ADJ
hsn-1065	159	10	package	package	NOUN
hsn-1065	159	11	for	for	ADP
hsn-1065	159	12	the	the	DET
hsn-1065	159	13	social	social	ADJ
hsn-1065	159	14	sciences	sciences	PROPN
hsn-1065	159	15	(	(	PUNCT
hsn-1065	159	16	spss	spss	PROPN
hsn-1065	159	17	)	)	PUNCT
hsn-1065	159	18	version	version	NOUN
hsn-1065	160	1	[	[	X
hsn-1065	160	2	insert	insert	NOUN
hsn-1065	160	3	version	version	NOUN
hsn-1065	160	4	,	,	PUNCT
hsn-1065	160	5	e.g.	e.g.	ADV
hsn-1065	160	6	,	,	PUNCT
hsn-1065	160	7	25.0	25.0	NUM
hsn-1065	160	8	]	]	PUNCT
hsn-1065	160	9	.	.	PUNCT
hsn-1065	161	1	reults	reult	NOUN
hsn-1065	161	2	were	be	AUX
hsn-1065	161	3	expressed	express	VERB
hsn-1065	161	4	as	as	ADP
hsn-1065	161	5	mean	mean	NOUN
hsn-1065	161	6	±	±	NUM
hsn-1065	161	7	standard	standard	ADJ
hsn-1065	161	8	deviation	deviation	NOUN
hsn-1065	161	9	(	(	PUNCT
hsn-1065	161	10	sd	sd	NOUN
hsn-1065	161	11	)	)	PUNCT
hsn-1065	161	12	.	.	PUNCT
hsn-1065	162	1	independent	independent	ADJ
hsn-1065	162	2	sample	sample	PROPN
hsn-1065	162	3	t	t	PROPN
hsn-1065	162	4	-	-	PUNCT
hsn-1065	162	5	tests	test	NOUN
hsn-1065	162	6	were	be	AUX
hsn-1065	162	7	used	use	VERB
hsn-1065	162	8	to	to	PART
hsn-1065	162	9	compare	compare	VERB
hsn-1065	162	10	the	the	DET
hsn-1065	162	11	mean	mean	ADJ
hsn-1065	162	12	values	value	NOUN
hsn-1065	162	13	between	between	ADP
hsn-1065	162	14	cad	cad	PROPN
hsn-1065	162	15	patients	patient	NOUN
hsn-1065	162	16	and	and	CCONJ
hsn-1065	162	17	controls	control	NOUN
hsn-1065	162	18	,	,	PUNCT
hsn-1065	162	19	as	as	ADV
hsn-1065	162	20	well	well	ADV
hsn-1065	162	21	as	as	ADP
hsn-1065	162	22	between	between	ADP
hsn-1065	162	23	male	male	ADJ
hsn-1065	162	24	and	and	CCONJ
hsn-1065	162	25	female	female	ADJ
hsn-1065	162	26	subgroups	subgroup	NOUN
hsn-1065	162	27	.	.	PUNCT
hsn-1065	163	1	pearson	pearson	PROPN
hsn-1065	163	2	correlation	correlation	NOUN
hsn-1065	163	3	was	be	AUX
hsn-1065	163	4	used	use	VERB
hsn-1065	163	5	to	to	PART
hsn-1065	163	6	determine	determine	VERB
hsn-1065	163	7	the	the	DET
hsn-1065	163	8	relationship	relationship	NOUN
hsn-1065	163	9	between	between	ADP
hsn-1065	163	10	aptt	aptt	PROPN
hsn-1065	163	11	,	,	PUNCT
hsn-1065	163	12	rbc	rbc	PROPN
hsn-1065	163	13	,	,	PUNCT
hsn-1065	163	14	and	and	CCONJ
hsn-1065	163	15	wbc	wbc	PROPN
hsn-1065	163	16	.	.	PUNCT
hsn-1065	164	1	a	a	DET
hsn-1065	164	2	p	p	NOUN
hsn-1065	164	3	-	-	PUNCT
hsn-1065	164	4	value	value	NOUN
hsn-1065	164	5	<	<	X
hsn-1065	164	6	0.05	0.05	NUM
hsn-1065	164	7	was	be	AUX
hsn-1065	164	8	considered	consider	VERB
hsn-1065	164	9	statistically	statistically	ADV
hsn-1065	164	10	significant	significant	ADJ
hsn-1065	164	11	.	.	PUNCT
hsn-1065	165	1	3.results	3.results	NUM